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Abbreviations
Aa Amino acid
ADH Alcohol dehydrogenase
APS Ammoniumperoxidisulfat
ATP Adenosine triphosphate
BCS Bathocuproine sulfonate
BSA Bovine serum albumin
CMV Cytomegalovirus
CMXRos Chloromethyl-X-rosamine
Conc Concentration
COX Cytochrome c oxidase
C-terminus Carboxyl-terminus
Cu Copper
DMEM Dulbecco's Modified Eagle medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonuleic acid
dNTP Deoxynucleosidtriphosphate
DTT Dithiothreitol
EDTA Ethylendiamine-tetraacetic acid
EGFP Enhanced green fluorescent protein
FADH2 Flavin adenine dinucleotide (reduced form of FAD)
FCS Fetal Calf Serum
Gal Galactose
GSH Glutathione
GST Glutathione S-transferase
HRP Horseradish-peroxidase
IM Inner membrane
IMS Intermembrane space
IPTG Isopropyl-1-thio-ß-D-galactopyranoside
Kan Kanamycin
kDa Kilodalton
MCS Multiple cloning site
mt Mitochondrial
MT Metallothionein
n Nuclear
NADPH Nicotinamide adenine dinucleotide phosphate (reduced form
of NADP+)
Neo Neomycin
NP-40 Nonidet P-40
N-terminus Amino-terminus
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PMSF Phenylmethylsulfonyl fluoride
PVDF Polyvinylidene difluoride
RT Room temperature
SDS Sodium dodecyl sulphate
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TEMED N,N,N',N'-Tetramethylethylenediamine
TM Transmembrane
Tris Tris(hydroxymethyl)aminomethane
v/v Volume per volume
w/v Weight per volume
Amino acids
A Ala alanine M Met methionine
C Cys cysteine N Asn asparagine
D Asp aspartate P Pro proline
E Glu glutamate Q Gln glutamine
F Phe phenylalanine R Arg arginine
G Gly glycine S Ser serine
H His histidine T Thr threonine
I Ile isoleucine V Val valine
K Lys lysine W Trp tryptophan
L Leu leucine Y Tyr tyrosine
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Aim of the work
Human cytochrome c oxidase (COX), the last enzyme of the respiration pathway in
mitochondria, is a complex enzyme constituted from at least 13 subunits, 3 of which are
encoded by the mitochondrial DNA. The assembly process requires the involvement of
different chaperones. The catalytic core of the enzyme, consisting of the three mitochondrially
encoded subunits Cox1p, Cox2p and Cox3p, contains three copper atoms and two heme
groups. Because free copper is not available in the cells, specific copper chaperones are
necessary to deliver copper to the mitochondria and to COX. Studies in yeast suggest that the
transfer of copper to the mitochondria requires yCox17p* and that two proteins, ySco1p and
ySco2p, representatives of a large protein family, are involved in the insertion of copper in
COX. Sco proteins could perform this function by binding copper and transferring it to COX.
Alternatively, they could allow COX to assume a three-dimensional structure necessary for the
insertion of copper from another chaperone. This last function is performed in bacteria by
thioredoxin-like proteins. In human, two Sco proteins have been identified. Mutations in these
proteins have been associated with lethal COX deficiency in infants.
This work will be focused on the characterisation of both hSco proteins and of some mutant
forms found in patients. The intracellular localisation and the ability of the hSco proteins to
substitute for the yeast homologues should be analysed. It is planned to develop a yeast model
to characterise hSCO mutations. Recombinant hSco1p, hSco2p and mutant forms should be
purified and analysed for their ability to bind copper and to act as thioredoxins. To define the
pathway of the copper insertion, interaction with hCox17p and Cox2p will be analysed.
Moreover, the ability of the two proteins to form homomers and heteromers should be
examined.
*To distinguish between human and yeast, y is used to denote the yeast genes and proteins while
h is used to denote the mammal genes and proteins.
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1 INTRODUCTION
Mitochondria are small intracellular organelles present in the cytoplasm of aerobic eukaryotic
cells. They are surrounded by a double membrane, the outer membrane separates the
mitochondrion from the cytosol, the inner membrane is invaginated to form cristae which
protrude into and define the matrix of the organelle. Most human cells contains 500 to 2000
mitochondria, often dynamically interconnected in a complex reticular network. Some cell
types, like platelets, have only few mitochondria and red blood cells do not contain
mitochondria. In the last decade, a considerable body of evidence has accumulated implicating
defects in the mitochondrial (mt) energy-generating pathway, oxidative phosphorylation
(OXPHOS), in a wide variety of degenerative diseases. The ubiquitous nature of mitochondria,
the dual genetic control of the respiratory chain, and the peculiar rules of mt genetics
contribute to explain the extraordinary clinical heterogeneity of disorders associated with
defects of OXPHOS [1]. Abnormalities of the electron transport and OXPHOS system are
probably the most common cause of mt diseases.
1.1 The OXPHOS System
The OXPHOS system is the main process responsible for the production of energy in the form
of ATP in most animal tissues under most conditions. The human OXPHOS system contains at
least 83 polypeptides, 13 of which are encoded by mtDNA genes. From a genetic point of
view, the respiratory chain results from a coordinate expression of the nuclear (n) genome and
the mt genome. The human mtDNA is a circular double-stranded molecule of 16,569 base
pairs. It encodes 13 proteins, 2 rRNAs and 22 tRNAs [2]. Introns are absent and all coding
sequences are contiguous with each other and lack significant untranslated flanking regions.
All proteins encoded from mtDNA are directly involved in OXPHOS and include components
of complex I (encoded by ND1, ND2, ND3, ND4, ND4L, ND5, ND6), III (encoded by CYT
b), IV (encoded by COX1, COX2 and COX3) and V (encoded by A6 and A8). All other mt
proteins (around 1100) are transcribed from the respective nuclear genes, translated in the
cytoplasm and their products are imported into mitochondria.
The five multi-protein complexes involved in OXPHOS are located in the mt inner membrane.
Substrates feed electrons into the respiratory chain at different points. Electrons are passed
down the chain and protons are pumped into the mt intermembrane space. This creates the
electrochemical membrane potential which is used to drive ATP production through re-entry of
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protons via complex V. Complex I oxidises NADH, transfers electrons to ubiquinone (or
coenzyme Q, CoQ) and pumps protons to the intermembrane space. Complex II links the
tricarboxylic acid cycle and the respiratory chain: it converts succinate to fumarate, producing
reducing equivalents as FADH2 and transferring electrons to ubiquinone. Complex III
transfers electrons from ubiquinone to cytochrome c (cyt c) while pumping protons to the
intermembrane space. Complex IV transfers electrons from cyt c to molecular oxygen and
pumps protons to the intermembrane space. Complex V couples the proton gradient generated
by the respiratory chain to ATP synthesis. Fig. 1 shows the OXPHOS complexes and denotes
the associated diseases.
Fig. 1. Diseases associated with defects of OXPHOS.
OXPHOS complexes are composed of nDNA-encoded (blue) and mtDNA-encoded subunits (red). The
'vertical' flow of protons (H+) and the concomitant 'horizontal' flow of electrons (e-) through the
respiratory complexes and the two mobile electron carriers CoQ and cyt c result in the synthesis of
ATP from ADP at Complex V. Diseases associated with mutations in mt-encoded tRNA, and rRNA
are in pink. The diseases associated with specific complexes are indicated: diseases resulting from
mutations in mtDNA-encoded subunits are in red, from mutations in nDNA-encoded subunits are in
blue and from mutations in assembly factors are in dark blue. Details and abbreviations are given in
the text. (In part taken from [3])
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1.1.1 The OXPHOS system and diseases
Mitochondria are maternally inherited. After fertilisation of the oocyte, sperm mtDNA is
actively degraded [4]. Each mitochondrion may contain ten or more mtDNA molecules.
Usually all copies of mtDNA are identical (homoplasmy). Occasionally, however, mtDNA
mutations occur and there arise more populations of mtDNA (heteroplasmy). Heteroplasmic
mtDNA ought to be relatively common, considering that human mtDNA mutates 10-20 times
faster than nDNA as a result of inadequate proof-reading by mtDNA polymerase and limited
mtDNA repair capability [5-8]. Moreover mtDNA lacks protective proteins like histones and is
physically associated with the inner mt membrane where highly mutagenic oxygen radicals are
generated [9]. Mutations may arise frequently and when mutated gene copies accumulate over
a certain threshold, the deleterious effect is no longer suppressed by the coexisting wild-type
mtDNA and will be expressed phenotypically as a disease. The threshold for biochemical
expression may be around 60 % mutant for mtDNA deletions [10] and 85-95 % for tRNA
mutations [11, 12]. The degree of organ dysfunction will also depend on a tissue’s energy
requirement. Brain and muscle are highly dependent on OXPHOS and neurological illness and
myopathy are common features of mtDNA mutations. Mt diseases can have a wide variety of
inheritance patterns, maternal, Mendelian, and a combination of both. Adding to this
complexity is the fact that the same mtDNA mutation can produce quite different phenotypes
and different mutations can produce similar phenotypes.
A significant percentage of respiratory chain disorders is caused by mutations of the mtDNA.
Dysfunction of OXPHOS has also been associated with mutations in nuclear-encoded
OXPHOS subunits. A further group of diseases results from mutations in genes coding non
OXPHOS mt proteins and in genes coding non mt proteins.
1.1.1.1 Diseases associated with mtDNA mutations.
Most pathogenic mtDNA mutations affect the heart, in association with a variety of other
clinical manifestations that can include skeletal muscle, the central nervous system (including
eye), the endocrine system, and the renal system [13]. They include point mutations,
rearrangements (deletions and duplications) and depletion.
Mutations in tRNA and rRNA genes typically affect the translation of all 13 mtDNA-encoded
polypeptides, resulting in generalised OXPHOS deficiencies. Mutations in the tRNALeu gene
Introduction
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are associated with the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic
acidosis and stroke-like episodes) [14], mutations in the tRNALys gene are associated with the
MERRF syndrome (myoclonic epilepsy with ragged-red fibers) [15] and mutations in the 12S
rRNA gene are associated with the AID syndrome (antibiotic-associated deafness) [16].
Most mutations in genes coding for complex I subunits are associated with LHON syndrome
(Leber’s hereditary optic neuropathy), a degeneration of the optic nerve leading to almost
complete blindness [17-19].
Pathogenic mutations in the mt encoded subunit of complex III are associated with myopathies
[20].
Mutations in the three subunits of complex IV are associated with unrelated disorders
including myopathy, encephalomyopathy and anemia [21-28].
Pathogenic mutations of complex V have been associated with the NARP syndrome
(neuropathy, ataxia, and retinitis pigmentosa) [29] or the Leigh syndrome, depending on the
degree of heteroplasmy [30].
Large scale rearrangements of mtDNA can be either partial mtDNA deletions or more rarely
partial duplications. They are found in some 40 % of adult patients with mt diseases [31].
Three phenotypes are associated with these mutations: Kearns-Sayre syndrome (KSS) [32],
progressive external ophthalmoplegia (PEO) [33] and Pearson’s syndrome [34]. The
pathogenicity of mtDNA deletions is due to the loss of tRNA genes, whereas duplicated
mtDNAs do not lack any tRNA genes and are probably not pathogenic [35]. Depletion of
mtDNA, first described in 1991 [36], is an important cause of mt dysfunction in neonates and
infants. Patients show a severe reduction of mtDNA, up to 98 % in the most severe forms.
1.1.1.2 Diseases associated with mutations of nuclear genes encoding OXPHOS proteins.
The observation of familial cases with Mendelian inheritance and severe isolated defects of the
respiratory chain complexes not associated with mtDNA lesions suggests the presence of
nuclear genes as a source of respiratory chain deficiencies.
Mutations in nuclear-encoded OXPHOS subunits are rare. So far mutations have been
identified for complex I, associated with Leigh syndrome and complex II, associated with
Leigh syndrome or with a neoplastic transformation called hereditary paraganglioma (PGL),
characterised by benign carotid body tumors in the head and the neck [37].
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1.1.1.3 Diseases associated with mutations of nuclear genes encoding mt non OXPHOS
proteins.
The OXPHOS system is dependent on mt protein transport and assembly systems, and many
nuclear-encoded factors are necessary to maintain mtDNA structure and function.
Defects of mt protein import have been described in two patients with Mohr-Tranebjaerg
syndrome. They presented a truncated form of a chaperonin (DPPI) [38], homologous to the
yeast protein Tim8p, a member of the inner mt membrane transport machinery located in the
mt intermembrane space [39].
Mutations in genes coding for assembly factors have been described for hSURF1, hCOX11,
hSCO1 and hSCO2, four genes involved in the assembly and maintenance of complex IV (see
below). Recently a mutation in hBCS1L, a gene coding for an assembly factor for complex III,
was described in patients suffering from tubulopathy, encephalopathy and liver failure [40].
Defect in frataxin, a protein involved in intramitochondrial iron handling, is associated with
Friedreich’s ataxia (FRDA), characterised by progressive ataxia, neuropathy, skeletal
abnormalities and cardiomyopathy [41]. The causative mutation is an abnormally expanded
GAA triplet repeat in intron 1 of the gene [42]. This defect causes decreased frataxin
expression [43], with increased iron deposition in the heart and deficiencies in complex I-III
and aconitase, which contain iron-sulphur clusters [44].
Mutations in the gene coding for paraplegin, a mt protein with high degree of homology to
AAA proteins (ATPases associated with diverse cellular activities) are associated with
hereditary spastic paraplegia (HSP) [45]. Mitochondrial AAA proteins are ATP-dependent
metalloproteases and have chaperone-like activities, for example, they can activate the
assembly of respiratory chain complexes and can participate in protein quality control by
binding unfolded peptides and ensuring specificity of proteolysis [46]. The mt dysfunction in
HSP patients could result from impaired protein quality control, causing an accumulation of
misfolded proteins within the mt matrix.
Defect in copper homeostasis in the Wilson’s disease is associated with mutations in a copper
transporter P-type ATPase, called WND [47]. The WND protein exists in two isoforms, a 160
kDa form which localises to the trans-Golgi network and a 140 kDa form which localises to
mitochondria [48]. This isoform may play a role in the copper-dependent functions of mt
enzymes.
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1.1.1.4 Diseases associated with mutations of nuclear genes encoding non mitochondrial
proteins.
Huntington’s disease (HD) is caused by an expansion of a CAG repeat within the huntingtin
gene on chromosome 4 [49]. Mutant forms of huntingtin protein accumulate in the nucleus of
affected neurons [50]. Defects of complex II, III and aconitase have been described in HD
brain [51], but the mechanisms through which huntingtin with expanded polyglutamine repeats
cause mt dysfunction is unknown.
Mutations of the human cytosolic Cu/Zn superoxide dismutase 1 (hSod1p) are associated with
Amyotrophic Lateral Sclerosis (ALS) [52], a devastating paralytic disorder caused by motor
neurons degeneration. Because hSod1p reduces the potentially harmful superoxide radicals,
ALS could be a consequence of disturbed free radical homeostasis and resulting oxidative
stress. Mouse models show, besides the morphological alteration in motor neurons, massive mt
degeneration [53] and abnormal respiration chain functions [54]. Mutated hSod1p forms show
no loss of activity and a toxic gain-of-function has been postulated [55].
OXPHOS defects have also been reported in patients suffering from progressive supranuclear
palsy (PSP), a disorder characterised by rigidity, slowed movement, tremor and abnormal eyes
movement. The tau locus on chromosome 21 has been identified as a potential risk factor to
develop this disease [56]. Tau is a phosphoprotein that belongs to a family of microtubule-
associated proteins. In the adult human brain there are six tau isoforms, generated by
alternative splicing of exons 2, 3 and 10, which contain either three or four microtubule
binding domains [57]. In the PSP brain, there is a selective enrichment of tau isoforms
containing four microtubule binding domains (4-repeat tau), particularly the 64 and 69 kDa
isoforms that result from the splicing-in of exon 10 [58]. These two isoforms are
hyperphosphorylated [59]. One hypothesis to explain the hyperphosphorylation of tau is that
free radical-induced oxidative stress makes tau resistent to dephosphorylation [60].
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1.2 The cytochrome c oxidase
Complex IV or cytochrome c oxidase (COX) is a member of a superfamily of heme-copper
containing terminal oxidases. These oxidases contain either a heme O or a heme A moiety at
their active site. Both hemes differ from proto-heme having a farnesyl group instead of a vinyl
group on position 2 of the porphyrin ring. In addition, in heme A, the methyl group on position
8 of the porphyrin ring is replaced by a formyl group [61]. The nature of the electron input site
reflects a division in the cytochrome oxidase in two groups. In cytochrome c oxidase, reducing
equivalents are delivered from the soluble protein ferrocytochrome c. The quinol oxidases, in
prokaryotes, receive electrons from a lipid-soluble quinol.
Recently, crystal structures at a resolution of 2.8 Å have been reported for COX from bovine
heart [62]. The crystal structure shows that the mammalian oxidase contains 13 polypeptides in
equimolar amount and is present as a dimer in the membrane with limited contact between the
monomers. Each monomer contains two iron centres, heme a and heme a3 (also referred to as
cytochromes a and a3), two copper centres, CuA and CuB, a magnesium centre and a zinc
centre. From the 13 protein components, Cox1p Cox2p and Cox3p are encoded from mtDNA
and represent the catalytic core of the enzyme, while the remaining ten subunits (Cox4, 5a, 5b,
6a, 6b, 6c, 7a, 7b, 7c and 8) are nuclear-encoded. The subunits 6a, 7a and 8 have heart (H)- and
liver (L)-specific isoforms so that heart and skeletal muscle express the heart form whereas the
L isoform is ubiquitously expressed [63-65]. Fetal heart and skeletal muscle mainly express the
L isoform, switching to the heart-type after birth [66]. Cox1p, Cox2p and Cox3p are
considered to be crucial for the catalytic function of the enzyme because they contain the redox
active prosthetic groups and are homologous to COX subunits found in proteobacteria such as
Paracoccus denitrificans and Rhodobacter sphaeroides [61]. Cox1p has 12 transmembrane
helices and contains, in the membrane space, heme a and the oxygen-binding site, composed
of heme a3 and CuB. Cox2p has two transmembrane helices and contains, in the extra-
membranous domain exposed to the intermembrane space, the binuclear CuA centre. The metal
binding motif CxxxC (single letter amino acid code where x is any amino acid) provides 3 of
the 6 ligands for the formation of the CuA site. Cox2p receives the electrons from cyt c and
transfers them to heme a and finally to heme a3-CuB centre. Cox3p contains seven
transmembrane helices and has no metal centres, but it is essential for preserving the structure
integrity of the active site during turnover [67]. On the interface between Cox1p and Cox2p,
the Mg2+ binding site is located, whose function is still unknown. The nuclear encoded
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subunits are important for assembly or stability of the complex [68] or for optimal activity of
the oxidase [69-72].
1.2.1 Assembly of COX
Many bacterial oxidases have little more than the three core subunits to constitute a fully
functional complex. However, both mammalian and yeast systems have difficulty assembling a
functional complex unless the additional nuclear subunits are present. The structure of COX
from the yeast Saccharomyces cerevisiae closely resembles that of its mammalian counterpart
[73]. Genetic studies in yeast have identified many nuclear genes that are involved in the
correct assembly of the structural components. Many of these factors have human homologues.
Some of these factors act in a general manner and also affect the biogenesis of other mt
respiratory complexes. Among these are proteins involved in the mt protein import or sorting,
like heath shock proteins [74], chaperones, like the AAA family of ATPases, involved in the
clearing of unassembled and improperly folded polypeptides [75], proteins like prohibitins,
that stabilise or protect unassembled protein subunits [76], and Mba1p [77] and Oxa1p [78]
which are required for the insertion of proteins into the inner membrane from the matrix site.
Some of the other nuclear genes encode proteins that are specific for the assembly of COX.
These include factors involved in heme farnesylation (Cox10p) [79, 80], in the insertion of
Cox1p and Cox2p (yShy1p/hSurf1p) [81-83], and in the copper recruitment (Cox17p, Sco1p,
Sco2p and Cox11p) [84-87]. In addition to the above genes there are at least eight others that
have been proposed to function as assembly facilitators. Proteins required in the assembly of
COX are listed in Table 1. The assembly of the multi subunits oxidase apparently occurs in an
ordered sequence, but most of the details remain to be resolved. Two dimensional gel
electrophoresis performed on mt fractions from cultured human cells provides evidence for
four steps (S1-S4) [88] (Fig. 2). The first subunit to assemble is Cox1p. It is inserted into the
membrane from the matrix side probably with the aid of Oxa1p and forms a subcomplex with
Cox4p. hSurf1p is possibly involved in the insertion of Cox1p. Metabolic labelling
experiments have indicated that Cox1p assembles with Cox2p and Cox3p only after a lag
period of 1,5 h [89]. It was postulated [90] that during this time Cox1p is folded into the inner
membrane and that concurrently the heme a is buried inside the protein. Synthesis of heme A
from protoheme requires Cox10p, a 7 transmembrane helix protein of the inner mt membrane,
and could be take place before or after the insertion of heme A in Cox1p. Heme A promotes
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the binding of Cox1p with Cox2p [91]. In the next step the CuB-heme a3 centre is formed and
simultaneously Cox2p associates with Cox1p to stabilise the active site. It was postulated that
the insertion of CuA occurs during this phase [90]. The insertion of CuB could be generated at a
later stage [87]. Sco1p, Sco2p and Cox17p are probably involved in the copper transport to the
CuA site [84, 86, 92], but they might also facilitate copper transfer to the CuB site in concert
with Cox11p [87]. A larger complex is then formed by association with Cox3p and most of the
nuclear-encoded subunits lacking only Cox6ap and Cox7ap which are peripheral polypeptides
and are incorporated late.
Yeast
protein
Function Human
homologues
Associated disease Reference
yPet100p Incorporation of nuclear-
encoded subunits
Unknown Unknown [93]
yShy1p Insertion of Cox1p and Cox2p hSurf1p Leigh syndrome [82, 83, 94-99]
ySco1p Incorporation of copper hSco1p
hSco2p
Hepatic failure
Encephalomyopathy
[84, 85, 92,
100-108]
ySco2p Incorporation of copper hSco1p
hSco2p
Hepatic failure
Encephalomyopathy
[84, 92, 95,
109-111]
yCox17p Incorporation of copper hCox17p Unknown [84, 86, 112-
117]
yCox10p Farnesylation of protoheme hCox10p Tubulopathy [79, 80, 118-
120]
yCox11p Incorporation of CuB hCox11p Unknown [87, 105]
yCox14p Function in the late step of
assembly
Unknown Unknown [121]
yCox15p Hydroxylation of heme O hCox15p Unknown [122]
yCox18p Stabilises Cox2p and might
assist in its binding to Cox1p
Unknown Unknown [123]
yCox20p Processes the exported
precursor of Cox2p
Unknown Unknown [124]
yPet117p Unknown Unknown Unknown [125]
yPet191p Unknown Unknown Unknown [125]
Table 1. Proteins required for the assembly of COX.
Yeast proteins and their human counterparts specifically involved in the assembly of COX are listed.
Diseases associated with mutations in the assembly factors are indicated.
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Fig. 2. Model of COX assembly.
Bold letters denote subunits of COX. Red letters indicate the steps of the assembly pathway (S1-S4).
Prosthetic groups are indicated in blue and assembly factors are indicated in grey. See text for details.
1.2.2 The thioredoxin system in the COX assembly.
Thioredoxin is a small and ubiquitously expressed protein conserved from prokaryotes to
higher eukaryotes (for review see [126]). Thioredoxin is characterised by a CxxC active site
[127] and by a conserved fold consisting of four b-sheet and three flanking a-helices [128].
When thioredoxin is in a reduced state, the two active-site cysteines form a dithiol group that is
able to catalyse the reduction of disulfides in a number of proteins. Oxidised thioredoxin can
be reduced by NADPH through the catalytic action of the thioredoxin reductase. The other
major factor generally responsible for maintaining proteins in the reduced state in vivo is
glutathione and the glutaredoxin system. Thiol-disulfide reductases that belong to the
thioredoxin superfamily can have either reducing properties or oxidising properties. In
bacterial systems the electron transport of OXPHOS is localised to the cytoplasm membrane
and protons are pumped in the periplasm. A broad variety of periplasmic thiol-disulfide
oxidoreductases have been identified in recent years (for review see [129]). Like the
?
S1 (Cox1p)
Cox10p
heme a
    (a)
Oxa1p
Cox4p
S2 (Cox4p,
     Cox1p a)
Cox10p
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       (a3)
CuB
Cox11p
Sco1p?, Sco2p?,
Cox17p?
Cox2p
CuA
S2 (Cox4p,
Cox1p aa3/CuB,
Cox2p CuA)
Sco1p, Sco2p,
Cox17p
Cox3p
Cox5ap,
Cox5bp,
Cox6bp,
Cox6cp,
Cox7bp,
Cox7cp,
Cox8p
S3 S4
Cox6ap,
Cox7ap
Surf1p?
Oxa1p
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cytoplasmic thioredoxins and glutaredoxins, these periplasmic thiol-disulfide oxidoreductases
contain the conserved CxxC motif in their active site. Most of them have a domain that
displays the thioredoxin-like fold. In contrast to the cytoplasmic system, which consists
exclusively of reducing proteins, the periplasmic oxidoreductases have either an oxidising, a
reducing or an isomerisation activity. The periplasm of bacterial cells is an oxidising
environment and contains an apparatus for catalysing the formation of disulfide bonds,
involving in Escherichia coli two proteins, DsbA and DsbB [130]. Since the oxidising
conditions of the periplasmic compartment may be deleterious for certain proteins,
periplasmically oriented redox proteins exist which keep cysteines reduced during protein
biogenesis. Unlike other cytochromes, c-type cytochromes have two covalent bonds formed
between the two vinyl groups of heme and two cysteines of the protein. DipZ and CcsX are
required in Bordetella pertussis for the periplasmic reduction of the cysteines of
apocytochromes c before ligation [131]. In Bradyrhizobium japonicum, TlpA is essential for
the biogenesis of a functional cytochrome aa3 [132] which contains a binuclear CuA ligated by
two cysteine thiols, one methionine and two histidines [133]. The two cysteines must be in the
reduced state to act as ligands. TlpA could keep these cysteines in the reduced state during aa3
biogenesis [134]. Thioredoxins have also been identified in yeast mitochondria [135] and
mammalian mitochondria [136], and a role in protection against oxidative stress was proposed
in both cases. So far no data are available on an involvement of the thioredoxin system in the
COX assembly in eukaryotes.
1.2.3 Copper delivery to COX: the role of copper chaperones
The transport of copper is a controlled process. In excess, copper ions are highly toxic, because
they catalyse the formation of hydroxyl radicals with subsequent damage of lipids, proteins
and DNA [137]. Thus, proper correct trafficking is essential for cell vitality. In vitro most
copper enzymes easily acquire copper without auxiliary proteins. In vivo, free copper is not
available, being less than one atom of free copper per cell [138], and metallochaperones are
needed to transport copper to the site of utilisation (see Fig. 3). In blood copper is bound to
albumin and histidine. The predominant copper-containing protein in mammalian serum is
ceruloplasmin [139], a ferroxidase critical for iron metabolism. A candidate for copper uptake
in mammal cells is hCtr1p [140], which shows high similarity to the yeast high-affinity Cu-
transport proteins yCtr1p and yCtr3p [141, 142]. A putative low affinity mammalian Cu
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transporter, hCtr2p has also been identified [143]. Following entry, detoxification mechanisms
found across species include the binding of copper to specific proteins, e.g. metallothioneins
[144], and the transfer of copper into isolated cell compartments.
Fig. 3. Copper transport pathways in human cells.
Copper uptake is mediated by hCtr1p and hCtr2p. Cu chaperones (hCox17p, hCcsp, hHah1p)
distribute Cu to specific cellular compartments for incorporation in copper requiring enzymes. See text
for details.
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The transport of copper to mitochondria involves hCox17p [112]. The role of Cox17p as
metallochaperone was deduced from the ability of high levels of exogenous copper to
complement a ycox17 disruption mutant [86]. yCox17p is localised in the cytosol and in the
intermembrane space [113], acting as a shuttle between the two compartments. yCox17p binds
three copper ions per monomer in a polycopper cluster [115]. yCox17p forms oligomers and
the oligomeric state is important for its function [115]. The human homologue, hCOX17, can
complement the ycox17 disruption mutant [112]. The transfer of copper from Cox17p to COX
involves at least three proteins, Sco1p, Sco2p [84, 92] and Cox11p [87], but no data have been
so far published about an interaction between these proteins and Cox17p. The pathways for
assembly of CuA and CuB are probably distinct since cytochrome c oxidase containing CuA but
lacking CuB can be assembled in a cox11 null mutant in Rhodobacter sphaeroides [87].
yCox11p and its human homologue [105] show a conserved CFCF motif which is possibly
involved in the CuB insertion.
Two further copper pathways, to the secretion system and to the Cu/Zn superoxide dismutase
(Sod1p), have been described. Disruption of these copper pathways is involved in different
human diseases.
hHah1p [145] transfers copper to two proteins located in the Golgi network, the Menkes and
Wilson’s disease proteins (WND and MNK) [146, 147] which transport copper to the secretory
pathway for incorporation into copper containing enzymes like ceruloplasmin [139]. Elevated
Cu levels stimulate the trafficking of MNK to the plasma membrane where it may be involved
in copper efflux [148], and the traffic of WND to an unknown cytosolic vesicular compartment
[149]. A cleaved form of WND was reported to localise to mitochondria where it is suggested
to play a role in the mt copper homeostasis [48]. Both proteins are P-type ATPase [150], and
mutations in the respective genes lead to genetic disorders of copper metabolism. WND is
expressed in most tissues but predominantly in the liver and MNK is expressed in all tissues
except the liver. In the Wilson’s disease, toxic amounts of copper accumulate in liver and brain
resulting in cirrhosis and neuronal degeneration. Menkes disease is a neurodegenerative
disease caused by copper deficiency in a number of tissues. hHah1p interacts with its partners
in a copper-dependent fashion [151, 152]. Yeast homologues are known for WND and MNK
(Ccc2p) [153] and for hHah1p (Atx1p) [154]. Copper is bound by the conserved MxCxxC
motif present one time in hHah1p [155] and six times in the target ATPases [156, 157].
Sod1p is a cytosolic homodimeric copper and zinc-binding enzyme which protects the cells
against oxidative damage by catalysing the conversion of superoxide radicals to hydrogen
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peroxide and oxygen [158]. Recent evidences suggest that Sod1p is incapable of acquiring Cu
ions in vivo in the absence of its chaperone, Ccsp [138]. yCcsp [159] and hCcsp [160] are
composed of a three-domain structure [161-163]. Domain I contains a conserved MxCccC
domain, domain II has high sequence homology to Sod1p, domain III contains a CxC motif.
Domain I and II bind copper and can interact via a cysteine-bridged dicopper cluster [164].
The high degree of homology of domain II to Sod1p was postulated to be important in the
target recognition of Sod1p [165]. hCcsp can form homodimers [163] and the metal insertion
into ySod1p by yCcsp is accomplished by the formation of a heterodimer between the two
proteins [166]. This interaction is not copper dependent [165].
Copper delivery by chaperones appears to be a specific process. One chaperone cannot
substitute for the absence of another chaperone. A transitory interaction between the chaperone
and its target has been proposed and the docking between the two proteins presumably
involves electrostatic interactions [167]. The mechanism of copper transfer between the
chaperones and their target proteins are not clear but a ligand attack of the recipient protein on
the Cu ion of the chaperone is plausible, implicating a competitive exchange process [154].
1.2.4 COX deficiency
Isolated COX deficiency is the most frequent cause of respiratory chain defects primarily
affecting those organs with high energy demand, such as the brain, skeletal muscle, heart and
kidney and resulting in a variety of clinical manifestations including Leigh syndrome [82],
hepatic failure [168] and encephalomyopathy [169]. COX deficiency has been associated with
mutations in the three mt-encoded subunits, Cox1p, Cox2p and Cox3p [21-28], with large
scale deletions of the mtDNA [170] and with point mutations in mt tRNA genes [14] (MELAS
and MERRF syndrome). No mutations have been reported in any of the nuclear genes
encoding COX subunits, however, mutations in nuclear encoded proteins required for the
assembly of the COX complex have been identified in human diseases. In patients suffering
from Leigh syndrome mutations in the hSURF1 gene have been detected [82, 96, 97], and
hCOX10 mutations have been found to be the cause of tubulopathy and leukodystrophy [80].
Mutations in hSCO2 were described in infants who suffered from a fatal disorder with
hypertrophic cardiomyopathy as the predominant symptom [95, 109, 110]. Recently a first
report on mutations in the hSCO1 gene was published [108]. The key symptoms of the infant
patients were hepatic failure and ketoacidotic coma.
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1.2.4.1  hSurf1p
hSurf1p is an integral inner membrane protein. [99]. To date, 30 different mutations have been
reported in 40 unrelated patients [96]. The concentration of all COX-subunits except for
Cox5ap and Cox5bp is strongly reduced [98, 99]. The transcription [171] and translation [172]
of COX genes is normal, implicating a defective assembly or instability of the assembled
complex. Northern blot analyses have shown that hSURF1 mRNA is ubiquitously expressed
but expression in the brain appears to be low compared with other highly aerobic tissues like
heart, skeletal muscle and kidney [99]. As Leigh syndrome is primarily a central nervous
system disorder, it is clear that the protein, despite its low expression in the brain, plays a
crucial role in this tissue. Most of the identified mutations in hSURF1 patients predict
truncated proteins. The loss-of-function of this mutants is associated with the absence of
hSurf1p due to either mRNA instability, rapid protein degradation or both [173]. Recently,
missense mutations have been identified, which do not alter hSURF1 mRNA expression but
are able to prevent its function [97]. Blue native two-dimensional electrophoresis indicates that
the absence of hSurf1p causes the accumulation of early intermediates of COX assembly
(Cox1p and Cox1p associated with Cox4p) [173], suggesting that it is involved in the
incorporation of Cox2p. This crucial step is believed to produce the rapid „cascade-like“
assembly of the other COX subunits. Detection of residual amounts of fully assembled
complexes suggests a certain degree of redundancy of hSurf1p in COX assembly [173]. Defect
of COX activity in hSURF1 patients is widespread in all tissues of the body, including skin
fibroblasts and it is quite severe, although a residual activity ranging from 5 to 20 % [97] can
usually be found.
1.2.4.2 hCox10p
The yCOX10 gene encodes an heme A:farnesyltransferase [120]. The human homologue
encodes a protein predicted to contain seven to nine transmembrane domains localised in the
mt inner membrane [118]. The protein structure is conserved from bacteria to human, with the
amino acid sequence of transmembrane segments II to V being highly conserved [174].
Mutations in the hCOX10 gene have a major effect on the level of Cox2p, the steady-state
levels of the other subunits, including Cox1p, are relatively normal [80]. This is remarkable
because Cox1p in these patients cannot associate with heme aa3 prosthetic groups. This
suggests that the heme groups are not necessary to stabilise Cox1p and that assembled enzyme
complex may be present, protecting the subunits from proteolytic degradation by mt proteases
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[175]. hCOX10 is expressed in multiple tissues with highest expression observed in heart,
skeletal muscle, and testis [119].
1.2.4.3 The Sco proteins
Yeast was the first organism in which a member of the SCO gene family was identified and
characterised [106]. Mutants lacking the ySCO1 gene are respiratory deficient due to a COX
deficiency. This phenotype results from an incorrect COX-subunits assembly which leads to
proteolytic degradation of unassembled COX subunits, especially of Cox1p and Cox2p [102,
106]. ySco1p, which is anchored in the inner mt membrane [100], is thought to be required for
transfer of copper ions to Cox1p and/or Cox2p because over-expression of ySco1p can
suppress the respiratory deficiency of strains lacking yCox17p [84]. The presence in ySco1p of
a CxxxC motif, which is similar to the copper binding site of Cox2p, suggests that ySco1p
might be directly involved in copper binding. In line with this suggestion is the finding that the
mutational alteration of either one or both of the two cysteine residues of the motif affects the
function of the protein [85]. Alternatively, it was proposed that ySco1p could mediate the
insertion of copper without direct copper-binding, e.g. as a thioredoxin, which is required for
the formation of a binding-competent 3D-structure of the COX-subunits [176]. Chinenov
(2000) [176] reported the similarity of proteins of the Sco family to thiol-disulfide
oxidoreductases. The overall similarity is low, but cysteine residues and hydrophobic amino
acids in the active centre are conserved and the predicted secondary structure of ySco1p
display the thioredoxin-like fold. Moreover, a conserved histidine was proposed to activate a
sulfhydryl group of the active centre. Indeed, yeast Sco1p carrying a mutation of this histidine
was shown to be inactive [104].
Sequence analysis of the yeast genome revealed ySCO2, a gene with a high degree of identity
to ySCO1 [177]. The function of ySco2p is unclear: like in the case of ySco1p, over-expression
of this mt protein can suppress the lack of the mt copper-shuttle protein yCox17p in the
presence of enhanced copper concentrations, suggesting that it might be involved in mt copper
metabolism [84]. However, neither there is an obvious mutant phenotype after deletion of the
ySCO2 gene nor the over-expression of ySCO2 is capable to suppress the respiratory
deficiency of ysco1 null mutants [84]. A partially overlapping function of ySco1p and ySco2p
is suggested by the demonstration that chimeras of both proteins can substitue for ySco1p [85].
Sco proteins are conserved among prokaryotes and eukaryotes. All homologues present the
CxxxC motif. The best characterised homologues are SenC from Rhodobacter capsulatus
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[178], YpmQ from Bacillus subtilis [179], and PrrC from Rhodobacter sphaeroides [180]. B.
subtilis has two cytochrome oxidases, a cytochrome c oxidase, which contains cytochrome a,
a3, CuA and CuB, and a menaquinol oxidase which lacks the CuA centre [181]. Deletion of
YpmQ disrupts the expression of the cytochrome c oxidase but not of menaquinol oxidase,
suggesting that YpmQ is involved specifically in the assembly of CuA. SenC is required for an
optimal COX activity in Rhodobacter capsulatus, a photosynthetic bacterium [178]. The
cytochrome c oxidase of Rhodobacter capsulatus has no a CuA centre [182] and it was shown
that SenC has an additional role in regulating photosynthesis gene expression [178]. A similar
role was proposed for the homologous PrrC in Rhodobacter sphaeroides [180].
In the human genome two genes with a high degree of identity to ySCO1 have been identified,
hSCO1 located on chromosome 17p12-13 and hSCO2 located on chromosome 22q13.
The essential role of hSco proteins for mt function is evident by the recent finding of mutations
associated with fatal infantile COX deficiency. An overview of the so far known mutations is
shown in Fig. 4.
                                             MAMLVLVPGRVMRPLG hSco1p
 GQLWRFLPRGLEFWGPAEGTARVLLRQFCARQAEAWRASGRPGYCLGTRPLSTARPPPPW hSco1p
                       MLLLTRSPTAWHRLSQLKPPVLPGTLGGQALHLRSWLL hSco2p
 SQKGPGDSTRPSKP-GPVSWKSLAITFAIGGALLAGMKHVKKEKAEKLEKERQRHIGKPL hSco1p
 SRQGPAETGGQGQPQGPGLRTRLLITGLFGAGLGGAWLALRAEKERLQQQKRTEALRQAA hSco2p
 LG-GPFSLTTHTGERKTDKDYLGQWLLIYFGFTHCPDVCPEELEKMIQVVDEIDSITTLP hSco1p
 VGQGDFHLLDHRGRARCKADFRGQWVLMYFGFTHCPDICPDELEKLVQVVRQLEAEPGLP hSco2p
 DLTPLFISIDPERDTKEAIANYVKEFSPKLVGLTGTREEVDQVARAYRVYYSPGPKDEDE hSco1p
 PVQPVFITVDPERDDVEAMARYVQDFHPRLLGLTGSTKQVAQASHSYRVYYNAGPKDEDQ hSco2p
 DYIVDHTIIMYLIGPDGEFLDYFGQNKRKGEIAASIATHMRPYRKKS              hSco1p
 DYIVDHSIAIYLLNPDGLFTDYYGRSRSAEQISDSVRRHMAAFRSVLS             hSco2p
Fig. 4. Alignment of hSco1p and hSco2p sequences.
Identical residues are in blue. The putative copper binding site is boxed, the known point mutations
and stop mutations (X) are in red.
X
L
F
K
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Mutations in hSCO2 are associated with muscular hypotonia, hypertrophic cardiomyopathy
and encephalopathy. Each patient is heterozygous for a single mutation. Mutations in hSCO2
have now been described in a total of 9 unrelated patients, each carrying a particular
(“common”) mutation at position 140 (E140K) with a stop or a missense mutation on the other
allele in 6 cases [95, 109] and 3 being homozygous for the E140K mutation [110]. A R20P
mutation was identified in patients and in healthy controls suggesting that it is a common
polymorphism. The E140K mutation, found in all patients, is near the predicted CxxxC copper
binding motif and changes a highly conserved negatively charged glutamate to a positively
charged lysine. It was postulated that this mutation could interfere with the copper binding of
the protein [95]. The S225F mutation is located next to the highly conserved His 224 and
converts an uncharged polar to an hydrophobic residue. His 224 was discussed as potential
ligand for copper [179], or as activator of the catalytic function in the case of the thioredoxin
model [176]. The R171W mutation converts a positive charged arginine to a polar tryptophan.
The known stop mutations occur at position 53 and 90, respectively, and truncate the protein
upstream the CxxxC motif. A proof for the causal role of hSCO2 mutations in COX deficiency
has not been obtained in human cells so far, however the transfer of a normal chromosome 22
into COX-deficient fibroblasts of a patient carrying the E140K and the R171W mutations
resulted in a rescue of COX activity [109]. Northern blot analysis shows hSCO2 transcripts in
all human tissues, with stronger signals present in heart, skeletal muscle, brain, liver and
kidney [95]. Biochemical measurements in biopsy samples show that heart and skeletal muscle
have a strong reduction in COX activity (0-18 % rest activity) whereas liver and fibroblasts
have mild COX deficiency (16-50 %) [95, 109]. Immunohistochemistry of skeletal muscle
shows severe reduction of Cox1p and Cox2p, and a small reduction of Cox4 and Cox5a [95].
Western blot analysis of fibroblasts shows a very small reduction in the steady-state levels of
either mtDNA- or nuclearly-encoded subunits [109]. Tissue-specific reduction of COX activity
has also been described in a distinct form of Leigh syndrome in the French Canadian
population. These patients show very low COX activity in liver and brain and relatively high
activity in muscle and fibroblasts [183]. In this case the gene defect is still unknown. A
genotype/phenotype correlation was observed: the progress of the disease was more severe in
patients carrying an additional stop mutation than in those with an additional point mutation
and again lesser in homozygous patients (E140K/E140K). Jaksch et al. discuss that this
observation could hint at the formation of dimers or higher order oligomers [110]. Most
probably, two stop mutations in hSCO2 would cause early prenatal deleterious effects. Patients
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with the E140K homozygous mutation show a less progressive clinical course, with an initial
typical Leigh syndrome, a progressive decline of the COX activity (30 % in the final state) and
the fatal hypertrophic cardiomyopathy occurring late. In these patients a predominant
involvement of the peripheral nervous system was observed and it was hypothesised that the
progressive cardiomyopathy in hSCO2 patients is not necessarily an early symptom of this
disorder, but it is indicative of a specific aerobic energy supply threshold for cardiac function
[110]. Again, fibroblasts show a relatively high residual COX activity. Interestingly, copper
uptake of cultured fibroblasts from a homozygous patient was significantly increased,
indicating an involvement of hSco2p in the copper metabolism. Engineered in the ySCO1 gene
of haploid yeast, the common mutation did not result in a measurable phenotype while the
S225F mutation caused a loss of respiratory competence resulting from a partial but incorrect
assembly of COX [92]. The assembled COX in this mutant specifically lacks Cox2p while
Dysco1 mutant lacks Cox1p, too. The yeast strain carrying the S240F mutation in ySCO1
(corresponding to the S225F mutation in the human gene) is the first example of a yeast COX
assembly mutant that can produce a partially assembled COX complex without undergoing the
proteolytic pathway [184]. The specific lack of Cox2p strongly suggests the involvement of
Sco proteins in the addition of copper to the CuA-site after Cox2p has been incorporated in the
assembling enzyme and a stabilising influence of Sco proteins on the assembling enzyme.
Recently a first report on mutations in the hSCO1 gene was published [108]. The key
symptoms of the two infant patients were hepatic failure and ketoacidotic coma. Sequence
analysis revealed compound heterozygosity for the hSCO1 gene. One of the hSCO1 alleles
harboured a -2 bp frame shift mutation resulting in a premature stop codon. The mutated
mRNA was highly unstable. The other allele showed a missense mutation, resulting in a
substitution of a proline at position 174, immediately adjacent to the CxxxC motif, by a leucine
(P174L). Prolines are known to bend proteins and it was proposed that this substitution can
modify the tertiary structure of the copper binding motif. This finding suggests that the P174L
mutation interferes with the function of the hSCO1 gene product, however, direct experimental
proof for the pathogenicity of this mutation is lacking. COX deficiency was found in liver (10
% residual activity), in muscle (0,5 % residual activity), in lymphocytes and skeletal muscle.
COX deficiency was observed, too, in chorionic villi and amniotic cell fluid in two male
fetuses of the same family [108]. Northern blot analysis shows hSCO1 transcripts in all human
tissues, with the stronger signals present in heart, skeletal muscle, brain, liver and kidney, like
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hSCO2. The steady-state level of hSCO1 transcripts in these tissues was higher than that of
hSCO2 transcripts [95].
Despite the similar expression patterns and the predicted similar function, the consequences of
hSCO1 mutations are markedly different from those caused by hSCO2 mutations. So far no
data are available to explain the clinical discrepancies .
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2 MATERIALS AND METHODS
2.1 Materials
2.1.1 Instruments
LI-COR DNA sequencer (model
4000/4200;)
MWG-BIOTECH
SenSys Digital CCD camera INVITRO SYSTEM
Atom emission spectroscope: PGS2 ZEISS, Jena
Atom absorption spectroscope: SpectrAA
10 GTA-96
VARIAN, Darmstadt
FPLC system AMERSHAM PHARMACIA BIOTECH
French Press SLM-AMINCO
Swing-out centrifuge HETTICH
CO2 incubator WTB BINDER
Dounce homogeniser BRAUN
2.1.2 Materials
5´ IRD800-labelled primers MWG-BIOTECH
Acrylamide/Bisacrylamide ROTH
Coomassieâ Brilliant blue G250 MERCK
Copper Standards FLUKA
Cytochrome c SIGMA
Dithiothreitol SIGMA
DMEM 4500 mg/l D-glucose, with non
essential amino acids, without L-glutamine
and sodium pyruvate
GIBCO-BRL
dNTP’s GIBCO-BRL
ECLplus-SystemTM AMERSHAM PHARMACIA BIOTECH
FCS GIBCO-BRL
Gel Blotting Paper SCHLEICHER & SCHUELL
Geneticin GIBCO-BRL
Glutamine GIBCO-BRL
GSH-Sepharose 4B AMERSHAM PHARMACIA BIOTECH
Human thioredoxin IMCO, STOCKHOLM
Human thioredoxinreductase IMCO, STOCKHOLM
ImmobilonTM-P PVDF-Membrane MILLIPORE
Insulin SIGMA
IPTG SIGMA
MitoTrackerâ Red CMXRos MOLECULAR PROBES
NADPH SIGMA
NP-40 SIGMA
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PBS without calcium and magnesium GIBCO-BRL
Placenta cDNA bank CLONTECH
PMSF SIGMA
Precision Protein StandardsTM BIO-RAD
Primers MWG-BIOTECH
Protein G-Agarose SANTA CRUZ BIOTECHNOLOGY
Proteinase inhibitors BOEHRINGER MANNHEIM
PVDF (ImmobilonTM, 0,45 µm) MILLIPORE
Pwo-Polymerase BOEHRINGER MANNHEIM
Restriction enzymes GIBCO-BRL
Spectral plates B + G BANSE UND GROHMAN
T4-DNA-Ligase PROMEGA
TEMED GIBCO-BRL
TfxÔ-20 liposome reagent PROMEGA
Thioredoxin IMCO
Thrombin SIGMA
Tissue culture flasks SARSTEDT
Trypsin (0,05 % Trypsin, 0,02 % EDTA) GIBCO-BRL
Tween 20 MERCK
X-ray films AMERSHAM PHARMACIA BIOTECH
2.1.3 Kits
Jetquick PCR Purification Spin Kit GENOMED
Jetquick Gel Extraction Spin Kit GENOMED
Jetquick Plasmid Miniprep Spin Kit GENOMED
DC-Protein Assay BIO-RAD
Thermo-Sequenase fluorescent labeled
primer cycle sequencing kit with 7-deaza-
dGTP
AMERSHAM PHARMACIA BIOTECH
2.1.4 Antibodies
Dilution in 1x TBS-T with 5 %
(w/v) skimmed milk powder
Mouse-Anti-yCox1p (MOLECULAR PROBES) 1:400
Mouse-Anti-yCox2p (MOLECULAR PROBES) 1:250
Mouse-Anti-hCox2p (MOLECULAR PROBES) 1:250
Mouse-Anti-Porin (MOLECULAR PROBES) 1:1000
Rabbit-Anti-ySco1p (Buchwald et al., 1991) 1:3000
Mouse-Anti-EGFP (ROCHE) 1:1000
Rabbit-Anti-EGFP (SANTA CRUZ) 1:500
Sheep-Anti-mouse IgG-HRP (AMERSHAM
PHARMACIA BIOTECH)
1:5000
Donkey-Anti-rabbit IgG-HRP (AMERSHAM
PHARMACIA BIOTECH)
1:5000
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2.1.5 Strains
2.1.5.1 Escherichia coli (E. coli)
Strain Genotype Reference
DH5a F80dlacZDM15, recA1, endA1, gyrA96, thi-1, hsdR17
(rK
-, mK
+), supE44, relA1, deoR, D(lacZYA-argF)U169
[185]
BL21 F-[dcm], ompT, [lon], hsdS(rB-mB-) gal [186]
2.1.5.2 Saccharomyces cerevisiae (S. cerevisiae)
Strain Genotype Reference
GR20 MATa, ura3-251, ura3-379, ura3-228, leu2-3, leu2-112,
his3-11, his3-15, SCO1::URA3, [rho+]
[106]
2.1.5.3 Human cells
Strain Reference
HeLa [187]
HeLa 17A3 This work
2.1.6 Media
2.1.6.1 E. coli-media
LB 1,0 % (w/v) Tryptone
0,5 % (w/v) Yeast extract
0,5 % (w/v) NaCl
2,0 % (w/v) Agar (for LB-Plates)
Marker selection 100 µg/ml Ampicillin
30 µg/ml Kanamycin
2.1.6.2 S. cerevisiae-media
YPD 1,0 % (w/v) Yeast extract
2,0 % (w/v) Peptone
2,0 % (w/v) Glucose
2,0 % (w/v) Agar (for YP-Plates)
YPGal 1,0 % (w/v) Yeast extract
2,0 % (w/v) Peptone
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2,0 % (w/v) Galactose
2,0 % (w/v) Agar (forYP-Plates)
YPGly 1,0 % (w/v) Yeast extract
2,0 % (w/v) Peptone
3,0 % (v/v) Glycerol
2,0 % (w/v) Agar (for YP-Plates)
WO 1,7 g/l Yeast nitrogen base
5,0 g/l Ammonium sulphate
2,0 % (w/v) Agar (for MM-Plates)
2,0 % (w/v) Glucose
for selection with YEp351 in GR20 add
3,0 g/l L-Histidine
WO-Gal 1,7 g/l Yeast nitrogen base
5,0 g/l Ammonium sulphate
2,0 % (w/v) Agar (for MM-Plates)
2,0 % (w/v) Galactose
for selection with YEp351 in GR20 add
3,0 g/l L-Histidine
2.1.6.3 Human cells media
Complete medium DMEM
10 % (v/v) FCS
2 mM Glutamine
Incomplete medium DMEM
2 mM Glutamine
Freezing solution (10 ml) DMEM
20 % DMSO
20 % FCS
2.1.6.4 Buffers
TBE 90 mM Tris
90 mM Boric acid
2,5 mM EDTA
TBS 137 mM NaCl
20 mM Tris-HCl (pH 7,4)
TBS-T 1 x TBS
0,1 % (v/v) Tween 20
PBS 140 mM NaCl
2,7 mM KCl
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10,1 mM Na2HPO4
1,8 mM KH2PO4
PBS-DTT 140 mM NaCl
2,7 mM KCl
10,1 mM Na2HPO4
1,8 mM KH2PO4
1 mM DTT (freshly added)
MTE 1,8 mM KH2PO4, pH 7,3
0,65 M Mannitol
20 mM Tris-HCl, pH 7,1
1 mM EDTA
1 mM PMSF (freshly added)
Homogenisation buffer 20 mM Hepes-KOH, pH 7.5
250 mM Sucrose
1 mM EDTA
10 mM MgCl2
0,1 mM PMSF
10 mM KCl
1 mM DTT (freshly added)
WM 250 mM Sucrose
10 mM Tris-HCl, pH 7,8
2 mM EDTA
Lysis buffer 150 mM NaCl
50 mM Tris, pH 8
1 % (v/v) NP-40
1 mM DTT (freshly added)
add 1X Proteinase inhibitors before use
Proteinase inhibitors stock solution
(1000X)
5 mg/ml Chymostatin
in DMSO 5 mg/ml Antipain
5 mg/ml Leupeptin
5 mg/ml Pepstatin
5 mg/ml Aprotinin
2.1.6.5 Solutions for SDS-PAGE
Running gel (12 %) 375 mM Tris-HCl, pH 8,8
12 % (w/v) Acrylamide
0,32 % (w/v) Bisacrylamide
0,1 % (w/v) SDS
0,1 % (w/v) Ammonium persulfate
0,1 % (v/v) TEMED
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Stacking gel 125 mM Tris-HCl, pH 6,8
4 % (w/v) Acrylamide
0,1 % (w/v) Bisacrylamide
0,1 % (w/v) SDS
0,1 % (w/v) Ammonium persulfate
0,1 % (v/v) TEMED
Running buffer 25 mM Tris
192 mM Glycine
0,1 % (w/v) SDS
6 x loading buffer 300 mM Tris-HCl, pH 6,8
30 % (w/v) Glycerol
10 % (w/v) SDS
0,1 % (w/v) Bromphenol blue
600 mM DTT or 5 % ß-mercaptoethanol
(freshly added)
Coomassie blue staining 42 % (v/v) Methanol
17 % (v/v) Acetic acid
0,1 % (w/v) Coomassie brilliant blue
G250
Destaining solution 30 % (v/v) Methanol
7 % (v/v) Acetic acid
2.1.6.6 Solutions for Western blot
Transfer buffer 192 mM Glycine
25 mM Tris
5,0 % (v/v) Methanol
0,1 % (w/v) SDS
Ponceau S staining 0,5 % (w/v) Ponceau S
1 % (v/v) Acetic acid
Blocking solution TBS-T
5 % (w/v) skimmed milk powder
2.1.6.7 Solutions for the Bradford assay
Bradford solution 0,01 % (w/v) Coomassie brilliant blue
G250
5 % (v/v) Ethanol
10 % (v/v) H3PO4
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2.1.7 Vectors
Vector Genetic marker Reference
YEp351 Ampr, LEU2, 2 µ, lacZ‘ [188]
p415 ADH Ampr, LEU2, CEN-ARS, ADH-promoter [189]
pGEX-4T-3 Ampr, Taq-promoter/GST-ORF/ MCS,
lacIq-ORF
AMERSHAM PHARMACIA
BIOTECH
pEGFP-N1 Kanr/Neor, CMV-promoter, MCS,
EGFP-ORF,
CLONTECH
2.1.8 Primers
primer Sequence (5‘ ® 3‘) enzyme
site
 1 TATAGGATCCATATGCTGCTGCTGACTCGGAGCCC BamHI
 2 TATAGGATCCGTCGACTCAAGACAGGACACTGCGG BamHI,
SalI
 3 TATATAGGATCCATGGCGATGCTGGTCCTAGTACCC BamHI,
 4 TATATATAGTCGACCTAGCTCTTTTTTCTGTATGGCCT SalI
 5 GTCCTCGAGCTCCCAATTGAAACTAAATTG SacI
 6 AGGGAGAAA/GAGAGGCTGCAGCAGCAAAAG
 7 CAGCCTCTC/TTTCTCCCTGTTGAAGAAATA
 8 CTGGATAAG/CTGGTGCAGGTGGTGCGGCAG
 9 CTGCACCAG/CTTATCCAGTTCATCAGGACA
 10 CAGCCATTA/TTCATCACTGTGGACCCCGAGCGG
 11 AGTGATGAA/TAATGGCTGCAGAGTAATACCATA
 12 CCAGCAAGA/GACGACGTTGAAGCCATGGCCCGC
 13 AACGTCGTC/TCTTGCTGGATCACAAGTTATAAA
 14 AGAGTATAC/TACAATGCCGGCCCCAAGGATGAG
 15 GGCATTGTA/GTATACTCTGTACTTCTTGCATGC
 16 CGTAGAAAA/GTACACGCGGTAACTGTGACTAGC
 17 CGCGTGTAC/TTTTCTACGCCTCCAAACGTCAAA
 18 TATATATGTCGACCTTCCCACGTTCACATAG SalI
 19 AGGGAGAAG/AAGGAAAAGGCAGAGAAGTTAGAGAAG
 20 CTTTTCCTT/CTTCTCCCTGTTGAAGAAATAAGAAAG
 21 CTGGACAAG/ATGATCCAAGTCGTGGATGAAATAGATAGC
 22 TTGGATCAT/CTTGTCCAGTTCATCAGGACAGAT
 23 AGTATAAAGCTTATGCTGCTGCTGACTCGGAGCCCC HindIII
 24 AGTATACCGCGGAGACAGGACACTGCGGAAAGCCGC SacII
 25 TATATAAAGCTTATGGCGATGCTGGTCCTAGTACCC HindIII
 26 TATATATACCGCGGGCTCTTTTTTCTGTATGGCCTCAT SacII
 27 AAGAACCTT/TTGGGTCAGTGGTTATTGATTTATTTTGGC
 28 CTGACCCAA/AAGGTTCTTCTCCGTAAACTCATT
 29 CTTGGGGGA/CCGTTTTCCCTCACAACTCATAC
 30 GGAAAACGG/TCCCCCAAGTGAAGGTTTACCGTA
 31 CCTGATGTCTGTCTAGAAGAACTAG
 32 CTAGTTCTTCTAGACAGACATCAGG
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 33 TGCCCAGACAAGCTGGAGAAGCTGGTG
 34 CTCCAGCTTGTCTG GGCAGATGTCAGGG
 35 GTGGACCACTTCATTGCCATCTACCTG
 36 GGCAATGAAGTGGT CCACGATGTAGTC
 37 GATGTCAGG/GGCGTGAGTGAAGCC
 38 ACTCACGCC/CCTGACATCGCCCCAGACGAGCTGG
 39 GACATCAGGGGCATGAGTGAAGCC
 40 ACTCATGCCCCTGATGTCGCCCCAGAAGAACTA
 41 TATATAAAGCTTATGCCGGGTCTGGTTGACTC HindIII
 42 TATATACCGCGGTATTTTAAATCCTAGGGCTCTCATGC SacII
 43 TATATAGGATCCAAGCACGTCAAGAAAGAAAAGGCA BamHI
 44 TATATAGGATCCAGGGCTGAGAAGGAGAGGCTG BamHI
 45 TATATATAGCGGCCGCTTACTACTTCAGGTAAAAGTCGGTC
CGCGGAGACAGGACACTGCGGAAAGCCGC
NotI,
SacII
uni-21* TGTAAAACGACGGCCAGT
rev-29* CAGGAAACAGCTATGACC
GST-for* GGGCTGGCAAGCCACGTTTG
GST-rev* CCGGGAGCTGCATGTGTCAG
hSco2-int-
rev*
AAACCAGGCTCTGCTTCCAG
hSco2-int-
vor*
GTGCAGCCTGTCTTCATCAC
hSco1-int-
rev*
AAGTAAAGGCTTGCCGATGT
EGFP-vor* CTGGTTTAGTGAACCGTCAG
EGFP-rev* ACGCTGAACTTGTGGCCGTT
EGFP-
rev2*
TTATGTTTCAGGTTCAGGGG
Table 2. Primers used for the plasmids construction and for sequencing.
The enzyme recognition sites are indicated in italic. The primer annealing regions are in bold,
overlapping sequences are underlined, (/) indicates the switch between two genes, the introduced
mutations are in red, (*) indicates 5’ IRD800 labelled sequencing primers.
2.1.9 Plasmids
Plasmid primers over-
lapping
primers
template protein
p415 ADH-hSco1p 3, 4 hSCO1 cDNA hSco1p
p415 ADH-hSco2p 1, 2 hSCO2 cDNA hSco2p
YEp351-ySco1p(1-95)/
hSco1p(117-301)
5, 4 19, 20 p415 ADH-hSco1p,
YEp351-ySco1p
ySco1p(1-95)/
hSco1p(117-301)
YEp351-ySco1p(1-158)/
hSco1p(180-301)
5, 4 21, 22 p415 ADH-hSco1p,
YEp351-ySco1p
ySco1p(1-158)/
hSco1p(180-301)
YEp351-ySco1p(1-95)/
hSco2p(83-266)
5, 2 6, 7 p415 ADH-hSco2p,
YEp351-ySco1p
ySco1p(1-95)/
hSco2p(83-266)
YEp351-ySco1p(1-
158)/hSco2p(144-266)
5, 2 8, 9 p415 ADH-hSco2p,
YEp351-ySco1
ySco1p(1-158)/
hSco2p(144-266)
YEp351-ySco1p(1-177)/
hSco2p(164-266)
5, 2 10, 11 p415 ADH-hSco2p,
YEp351-ySco1p
ySco1p(1-177)/
hSco2p(164-266)
YEp351-ySco1p(1-185)/ 5, 2 12, 13 p415 ADH-hSco2p, ySco1p(1-185)/
Materials and methods
32
hSco2p(172-266) YEp351-ySco1p hSco2p(172-266)
YEp351-ySco1p(1-222)/
hSco2p(209-266)
5, 2 14, 15 p415 ADH-hSco2p,
YEp351-ySco1p
ySco1p(1-222)/
hSco2p(209-266)
YEp351-ySco1p(1-158)/
hSco2p(144-208)/
ySco1p(223-295)
5, 18 16, 17 YEp351-ySco1p
(1-158)/hSco2p
(144-266), YEp351-
ySco1p
ySco1p(1-158)/
hSco2p(144-208)/
ySco1p(223-295)
YEp351-ySco1p(1-134)/
hSco1p(156-301)
5, 4 27, 28 p415 ADH-hSco1p,
YEp351-ySco1p
K1
YEp351-ySco1p(1-117)/
hSco1p(139-301)
5, 4 29, 30 p415 ADH-hSco1p,
YEp351-ySco1p
K2
YEp351-ySco1p(1-134)/
hSco1p(156-301)(P174L)
5, 4 31, 32 YEp351-ySco1p
(1-134)/hSco1p
(156-301)
K1L
YEp351-ySco1p(1-117)/
hSco1p(139-301)(P174L)
5, 4 31, 32 YEp351-ySco1p(1-
117)/hSco1p(139-
301)
K2L
pEGFP-hSco1p 25, 26 p415 ADH-hSco1p hSco1p-EGFP
pEGFP-hSco2p 23, 24 p415 ADH-hSco2p hSco2p-EGFP
pEGFP-hSco2p(E140K) 23, 24 33, 34 pEGFP-hSco2p hSco2p(E140K)-
EGFP
pEGFP-hSco2p(S225F) 23, 24 35, 36 pEGFP-hSco2p hSco2p(S225F)-
EGFP
pEGFP-hSco1pDcys 25, 26 37, 38 pEGFP-hSco1p hSco1pDcys-EGFP
pEGFP-hSco2pDcys 23, 24 39, 40 pEGFP-hSco2p hSco2pDcys-EGFP
pEGFP-hCox17p 41, 42 cDNA hCox17p-EGFP
pGEX-4T-3-hSco1p(C) 43, 4 pEGFP-hSco1p hSco1p(C)
pGEX-4T-3-hSco2p(C) 44, 2 pEGFP-hSco2p hSco2p(C)
pGEX-4T-3-
hSco2p(C)(E140K)
44, 2 pEGFP-
hSco2p(E140K)
hSco2p(C)(E140K)
pGEX-4T-3-
hSco2p(C)(S225F)
44, 2 pEGFP-
hSco2p(S225F)
hSco2p(C)(S225F)
pGEX-4T-3-
hSco2p(C)Dcys
44, 2 pEGFP-hSco2pDcys hSco2p(C)Dcys
pGEX-4T-3-
hSco1p(C)Dcys
43,.4 pEGFP-hSco1pDcys hSco1p(C)Dcys
pAU5-hSco1p 25, 45 pEGFP-hSco1p hSco1p-AU5
Table 3. List of the plasmids constructed in this work.
The name of the plasmids are indicated on the left and the resulting protein on the right, the numbers in
brackets indicate amino acids position. The primers and the templates used in the PCR are indicated.
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2.2 Methods
2.2.1 Plasmids
The oligonucleotide primers used for PCRs are listed in Table 2. The combination of primers
and the created constructs are listed in Table 3. The annealing temperature (Ta) of the primers
was calculated according to the following formula (MWG-BIOTECH):
Ta = 69,4°C +0,41 x (GC-Percent) – 650/Primer length – 6°C
The following mix was used:
Final concentration
Template 1 ng/µl
Upstream primer (100 pmol/µl) 1 pmol/µl
Downstream primer (100
pmol/µl)
1 pmol/µl
dNTP mix (each dNTP 10 mM) each dNTP 200µM
PCR puffer (10X) 1X
Pwo Polymerase (5 units/µl) 2 units
Total volume 100 µl
The following PCR programs were used:
General PCR
5 min 95°C
addition of Polymerase (“hot start”)
Initial denaturation 1X
1 min 94°C
1 min Ta
2 min 72°C
Denaturation
Annealing
Elongation
20X
5 min 72°C Final elongation 1X
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Overlay PCR
5 min 95°C
addition of Polymerase (“hot start”)
Initial denaturation 1X
1 min 94°C
1 min Ta
2 min 72°C
Denaturation
Annealing
Elongation
10X
1 min 94°C
1 min Ta + 5°C
2 min 72°C
Denaturation
Annealing
Elongation
20X
5 min 72°C Final elongation 1X
Standard techniques were used for restriction endonuclease analysis of DNA, ligation of DNA
fragments, transformations and recovery of plasmid DNA from E. coli [190]. Purification of
PCR products and plasmids was carried out with the kits listed in section 2.1.3.
The construct YEp351-ySco1p comprises the promoter, the coding region and the terminator
of ySCO1 [85]. A cDNA clone containing the hSCO2 gene was obtained from Luc Smink
(Sanger Centre, Hinxton, GB) and a cDNA clone containing the hSCO1 gene was provided by
Professor Massimo Zeviani (National Neurological Institute “C. Besta”, Milano, Italy).
Constructs p415 ADH-hSco1p and p415 ADH-hSco2p, in which the human genes are under
control of the ADH promoter, were obtained by cloning a PCR product in the vector p415
ADH.
Chimeras under the control of the ySCO1 promoter were created by overlap extension PCR
[191] and cloned into the vector YEp351. The mutant chimeras K1L and K2L, in which the
proline at position 174 of the original human wild type protein was substituted by leucine,
were obtained with overlap extension PCR and cloned in the YEp351 vector.
Plasmids pEGFP-hSco1p and pEGFP-hSco2p, in which the human genes are fused C-
terminally to the EGFP gene, were obtained by cloning a PCR product into the pEGFP-N1
vector.
Mutant genes coding for hSco2p(E140K), in which the aspartic acid at position 140 is changed
into a lysine and hSco2p(S225F), in which serine at position 225 is changed to phenylalanine,
were obtained by overlap extension PCR. The PCR products were cloned into the vector
pEGFP-N1 to create pEGFP-hSco2p(E140K) and pEGFP-hSco2p(S225F).
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Mutant gene coding for hSco2pDcys, in which the cysteine residues at positions 133 and 137
are substituted through alanines, and mutant gene coding for hSco1pDcys, in which the
cysteine residues at positions 169 and 173 are changed to alanines, were obtained by overlap
extension PCR. The PCR products were cloned into the vector pEGFP-N1 to create pEGFP-
hSco1pDcys and pEGFP-hSco2pDcys.
The C-terminal portion of hSco1p and hSco1pDcys was generated by amplification of the gene
region coding for Aa 113-301 of hSco1p and hSco1pDcys respectively. The PCR products
were cloned into the GST-fusion expression vector pGEX-4T-3 to obtain pGEX-4T-3-
hSco1p(C) and pGEX-4T-3-hSco1p(C)Dcys in which the hSCO1 genes are fused N-terminally
to GST gene. The C-terminal portions of hSco2p, hSco2p(E140K), hSco2p(S225F) and
hSco1pDcys were obtained by amplification of the gene region coding for Aa 79-266 of the
respective constructs. The PCR products were cloned into the vector pGEX-4T-3 to create
pGEX-4T-3-hSco2p(C), pGEX-4T-3-hSco2p(C)(E140K), pGEX-4T-3-hSco2p(C)(S225F)
pGEX-4T-3-hSco2p(C)Dcys and pGEX-4T-3-hSco1p(C)Dcys in which the hSCO2 genes are
fused N-terminally to GST gene.
The vector pAU5-hSco1p was constructed from the pEGFP-N1 vector by removing the EGFP
gene with the enzymes BamH1 and Not1 and by cloning a PCR product carrying the sequence
coding for hSco1p fused C-terminally with the sequence coding for the AU5 tag [192].
The hCOX17 gene was amplified from a placenta cDNA bank (CLONTECH) by PCR and
cloned into the plasmid pEGFP-N1 to create pEGFP-hCox17p.
2.2.2 Sequencing
DNA sequences were determined by the dideoxy chain termination method of Sanger [193]
using 5´ IRD800-labelled primers and the Thermo Sequenase fluorescent labelled primer cycle
sequencing kit with 7-deaza-dGTP as described by the manufacturer and the LI-COR DNA
sequencer. Primers used for sequencing are listed in Table 2. The annealing temperature of the
primers was calculated according the following formula (MWG-BIOTECH):
Ta = 69,4°C +0,41 x (GC-Percent) – 650/Primer length + 3°C
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2.2.3 Human cell methods
2.2.3.1 Cell Culture
HeLa cells were grown routinely in 75 cm2 flask in Dulbecco’s modified Eagle medium
(DMEM) containing 10 % fetal calf serum and 2 mM glutamine (complete medium). Cultures
were maintained at 37°C in a humidified atmosphere containing 5 % (v/v) CO2. Cultures were
splitted every three days by detaching the cells from the surface of the flask with the protease
trypsin. Before trypsin treatment, complete medium was removed and the adherent cells were
washed with 2 x 10 ml Ca2+- and Mg2+-free PBS. 1 ml trypsin was added and cells were
incubated at 37°C for 3 minutes. 10 ml complete medium were added to inactivate the trypsin
and the cells were pelleted by centrifugation for 5 min at 800 x g with a swing-out rotor at
room temperature. After removing the supernatant, cells were resuspend in 10 ml complete
medium and 10 µl of this suspension were used for determining the cell amount in a Neubauer-
counting chamber. 5x105 cells were transferred to a new flask.
For long-term storage, 1X107 cells were detached from the flask with trypsin, washed with 2 x
10 ml Ca2+- and Mg2+-free PBS and resuspend in 800 µl complete medium. 800 µl ice cold
freezing solution were then added drop by drop. The cells suspension was transferred to a
freezing vial and was stored for one year at –80°. For longer storage, cells were frozen
overnight at –80°C and then transferred to liquid nitrogen. To recover the frozen cells, the vial
was kept in a 37°C water bath. When the cells were thawed, the cells suspension was
transferred to a centrifuge tube. 1,8 ml complete medium (at room temperature) were added
and the cells were incubated for 5 minutes in a 37°C water bath. 3,6 ml complete medium were
added and the cells were again incubated for 5 minutes in a 37°C water bath. 1 ml complete
medium was finally added and the cells were centrifuged for 5 min at 800 x g at room
temperature. The medium was removed and 10 ml complete medium were added. The cells
were transferred to a tissue culture flask.
2.2.3.2 Transfection of HeLa cells
For transient expression cells were cultured in one-well TC chamber slides and transformed
using liposome-mediated transfection (TfxÔ-20) as described by the manufacturer. Cells were
seeded 1 day prior to transfection at 40-70 % confluence. For transfection of about 3 x 105
cells, 1 µg of plasmid DNA and 2 µl of liposome-solution (1 mM stock solution) in 1 ml
incomplete medium were used. Cells were washed with 2 x 10 ml Ca2+- and Mg2+-free PBS
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and the DNA/liposome mixture was added. After 2 h incubation in the CO2 incubator at 37°, 2
ml complete medium were added and the cells were incubated for further 14 hours.
Transfection efficiency was routinely high (approximately 50 %). Transfections in 100-mm
plates (3X106 cells) were performed with 20 µl DNA and 40 µl of liposome reagent in 10 ml
incomplete medium.
For stable transfection, cells were put under geneticinTM selection (final concentration: 500
µg/ml) 48 h after transfection. To improve selection, cells were successively replated to
eliminate untransfected cells. Geneticin-resistant clones were picked by ring cloning, regrown
in multiwell plates, and subsequently tested for the presence of an expressed transgene by
Western blot analysis and fluorescence microscopy.
2.2.3.3 Isolation of human mitochondria
Cells were detached from the flask as described in 2.2.3.1. and the cell pellet was washed twice
with PBS. The pellet was resuspend by gentle pipetting in 2 volumes of ice-cold
homogenisation buffer, kept on ice for 5 min and then homogenised in a dounce homogeniser
with 20 strokes. Disruption of the cells was monitored by microscopy. Nuclei and cell debris
were pelleted by two sequential centrifugations at 1200 x g for 3 min at 4°C. Mitochondria
from the post-nuclear supernatants were recovered by centrifugation at 12000 x g for 10 min at
4 °C. Mitochondrial pellet was washed once with 1 ml ice-cold wash-buffer (WM) and either
directly processed or frozen at  -80 °C. 800 µg mitochondria were obtained from 2x107 cells.
2.2.3.4 Preparation of HeLa cells mitochondrial lysate and whole lysate
Mitochondrial and whole cell lysate were prepared by lysing mitochondria (prepared as
described in section 2.2.3.3) or cells in lysis buffer for 1 h on ice. For 1x107 cells or 1 mg
mitochondria, 1 ml lysis puffer was used. Cells debris was removed by centrifugation at 3000
x g for 10 min at 4°C. Supernatant was collected after centrifugation at 13000 x g at 4° for 15
min.
2.2.3.5 Fluorescence microscopy
HeLa cells were subcultured in TC chamber slides and transfected as described above. For
staining of mitochondria cells were incubated for 30 min in the presence of 50 nM
MitoTrackerâ Red CMXRos. Cells were visualized with a Jena Lumar fluorescence
microscope 14 hours after transfection. EGFP has a fluorescence excitation maximum at 408
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nm and a fluorescence emission maximum at 507 nm. MitoTracker has a fluorescence
excitation maximum at 579 nm and a fluorescence emission maximum at 599 nm. Pictures
were taken with the SenSys Digital CCD camera and edited with the MetaView software
(INVITRO SYSTEM).
2.2.4 Yeast cells methods
2.2.4.1 Transformation
Yeast cells were transformed using the LiAc procedure [194].
2.2.4.2 Isolation of yeast mitochondria
Yeast transformants were grown to stationary phase in WO-Gal medium. Cells were harvested
by centrifugation at 3000 x g for 5 minutes. After washing with 1 ml ice-cold water, cells were
resuspended in 1 ml ice-cold MTE. Cells were lysed by vortexing vigorously for 5 min in the
presence of 500 µl glass beads (Æ 0,45 mm). Supernatants were collected to new tubes and
glass beads were washed once with 500 µl ice-cold MTE. The supernatant of the washing step
was added to the previous supernatants. Unbroken cells and the cell debris were removed by
centrifugation at 3000 x g for 3 min at 4°C. Mitochondria were pelleted by centrifugation at
13000 x g for 15 min at 4°C.
2.2.4.3 Determination of COX-activity
COX activity was determined as described by Tzagoloff et al. [195]. 50 µg of mitochondria
were solubilized in assay-buffer (50 mM potassium phosphate, pH 7,2; 0,5 % (v/v) Tween 80).
The enzyme reaction was started by addition of 50 µM reduced ferrocytochrome c and the
initial rate of oxidation was determined at room temperature by following the decrease in
absorbance at 550 nm.
2.2.5 Affinity purification of recombinant proteins
BL21 transformants harbouring plasmid pGEX-4T-3 or pGEX-4T-3 carrying the coding region
for the genes of interest were inoculated 1:100 from an overnight culture and grown at 30°C in
LB broth with 2 % (w/v) glucose and 100 µg/ml ampicillin until an absorbance of 0,8 at 600
nm was reached. The culture was induced with 100 µM IPTG. For isolation of proteins for
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atomic absorption spectroscopy 0,5 mM CuSO4 was added at the time of induction. After 30
minutes cells were harvested, washed twice in PBS-DTT and resuspended in PBS-DTT with
10 % (v/v) glycerol, 1 mM PMSF. Cells were lysed using a French press at 1000 psi 2 times
and cell debris was removed by centrifugation at 20000 x g at 4°C for 1 h. The supernatant was
incubated for 1 h at 4°C with 50 % (w/v) Glutathione (GSH)-Sepharose 4B suspension
equilibrated three times with 20 volumes PBS-DTT. GSH-Sepharose 4B was pelleted by
centrifugation and washed with PBS-DTT. Bound fusion protein was cleaved on the matrix
with thrombin in PBS-DTT at room temperature to eliminate the GST moiety. Proteins were
analysed by SDS-PAGE and stained with Coomassie Blue G-250.
2.2.6 In vitro interaction assay
20 µg of GST fusion proteins or GST alone were immobilized on GSH-Sepharose beads and
allowed to interact for 2 h at 4°C with cell lysate of 2x106 HeLa cells or with 800 µg
mitochondrial lysate (prepared as described in section 2.2.3.4). In some experiments
immobilised fusion proteins were loaded with copper by incubation with 200 µM CuSO4 and 1
mM DTT in TBS for 2 h at 4°C. Excess copper was removed by washing with 30 volumes
TBS. Following binding, the beads were washed extensively with 1x PBS-DTT containing 0,3
% (v/v) NP-40 and protein complexes were released by the addition of sample buffer with b-
mercaptoethanol and heating at 100° for 5 min. Samples were analysed in Western blot with
antibody against Cox2p or EGFP. In some experiments lysis puffer and wash solution without
DTT were used.
2.2.7 Immunoprecipitation
Immunoprecipitation of mitochondrial proteins were performed with anti-AU5 or anti-EGFP
antibodies. 1 mg mitochondria were lysed as described in section 2.2.3.4 and the supernatant
was incubated with 10 µl anti-AU5 antibody or anti-EGFP antibody for 3 h at 4°C on an
orbital shaker. 30 µl protein G-Sepharose were added and the samples were incubated for
further 2 h at 4°C. The beads were washed four times with 1 ml lysis buffer.
Immunoprecipitates were examined with Western blot analysis.
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2.2.8 Determination of the protein concentration
The protein concentration was determined using the DC protein-assay as described by the
supplier or using the Bradford method [196].
2.2.9 Western blot analysis
Proteins were separated on a 12 % polyacrylamide gel in the presence of SDS. Proteins were
transferred to a PVDF membrane using the semi-dry method for 1 h at RT at 1,5 mA/cm2.
Membranes were blocked over night at 4° C or 1 hour at room temperature with 5 % (w/v)
non-fat dry milk in TBS-T. Membranes were probed with polyclonal or monoclonal antisera
for 1 hour at room temperature and then washed three times for 10 minutes in TBS-T.
Horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies were used as
secondary antibodies. The secondary antibody was added to the membranes for 30 minutes at
room temperature and the membranes were then again washed three times for 10 minutes in
TBS-T. Antigen-antibody complexes were visualised by enhanced chemiluminescence (ECL
plus).
2.2.10 FPLC analysis
Proteins were separated on a Superdex 75 HR 10/30 gel filtration column. Column was
equilibrated with two column volumes of PBS-DTT. 500 µg of affinity purified proteins were
loaded and separation was performed at a flow rate of 0,5 ml/min at RT. Calibration of the
column for estimation of the molecular weights was performed using BSA and carbonic
anhydrase.
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2.2.11 Thioredoxin assay
The reaction mixture contained 500 mM NADPH, 55 mM insulin, 15 mM of a purified human
Sco protein or 5 mM human thioredoxin in 100 mM potassium phosphate, 2 mM EDTA, pH
7.4 [197]. The reaction was started by adding 80 nM human thioredoxin reductase. The
increase in turbidity as a result of the formation of the insoluble insulin B chain was followed
at 595 nm. The schema of the reaction is shown in Fig. 5.
Fig. 5. Reactions involved in the thioredoxin assay.
Thioredoxin, in its reduced state, reduce the disulfides of insulin and the free insulin B chain
precipitates. Oxidised thioredoxin is converted back to the reduced form by thioredoxin reductase with
the use of the electrons from NADPH.
2.2.12 Atomic emission spectroscopy
Atomic emission spectroscopy of affinity purified proteins (60 mg in PBS-DTT) was
performed with the plangrating spectrograph PGS2 using the arc method with carbon
electrodes. Spectral lines were recorded on a photo plate. Copper-specific lines at 324,75 nm
and 327,40 nm were identified with the spectral lines of iron as a reference. The principle of
the method is illustrated in Fig. 6.
Thioredoxin reduced + Insulin oxidised             Thioredoxin oxidised + Insulin reduced
turbidity
Thioredoxin reductase
       NADP+                                                       NADPH
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Fig. 6. Scheme of functioning of the atom emission spectroscopy.
The sample is submitted to a arc between two carbon electrodes. The radiation emitted from the
sample is separated by a grid in its wavelengths (l) and recovered on a film.
2.2.13 Atomic absorption spectroscopy (AAS)
Atomic absorption spectroscopy of affinity purified proteins in PBS-DTT isolated from E. coli
cells grown in the presence of 0,5 mM CuSO4, was performed with the SpectrAA 10 GTA-96.
The principle of functioning of the AAS is given in Fig. 7.
Fig. 7. Scheme of atom absorption spectroscopy for copper analysis.
A copper cavity cathode lamp emits the radiation which is directed to the graphite furnace. In the
graphite furnace the sample is atomised and absorbs part of the radiation. The monochromator
separates the analytic line (l = 324,75, in red), the intensity of which is measured by the detector. The
Lambert-Beer law fixes a relation between the decrease in the intensity of the initial radiation and the
concentration of the sample.
Lamp
Graphite
fornace
Monochromator
RilevatorDetector
Film
Carbon
electrodes
Grid
l
Samples
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3 RESULTS
3.1 Structural analysis of hSco proteins
The ySCO1 human homologous gene on chromosome 22 (hSCO2) [Sequence ID: AL021683]
was detected in the course of the systematic sequencing project of the human genome by Luc
Smink at the Sanger Centre. The homologue on chromosome 17 (hSCO1) [Sequence ID:
AF026852] was identified by the group of Massimo Zeviani [105]. hSCO1 contains six exons
and five introns, hSCO2 two exons and one intron.
The homologues of ySco1p share a high degree of similarity with respect to the primary
sequence and to their overall structure (Fig. 8). The BLAST 2 program [198] predicts 39 %
overall identity and 59 % similarity between hSco1p and ySco1p, and 41 % overall identity
and 59 % similarity between hSco2p and ySco1p. The overall identity between hSco1p and
hSco2p is 43 % and the similarity 63 %. The N-terminal part of ySco1p contains a
mitochondrial import sequence and a single predicted TM-region which directs the protein to
mitochondria and anchors it in the inner mitochondrial membrane [100]. The N-termini of both
hSco proteins are also reminiscent of mitochondrial pre-sequences in that they lack negatively
charged amino acids while they contain positively charged and hydroxylated amino acid
residues [199]. MitoProtII [200] predicts that hSco1p and hSco2p are very likely to be
mitochondrial proteins with a N-terminal import signal of 42 amino acids (Aa) for hSco1p and
of 31 Aa for hSco2p. The predicted molecular mass is 34 kDa for hSco1p (30 kDa without the
import sequence) and 29 kDa for hSco2p (26 kDa without the import signal). Computer
analysis of both human homologues with the MacMolly Tetraâ program (Mologen, Berlin)
predicts a single transmembranous domain between Aa 95-112 for hSco1p and Aa 61-78 for
hSco2p. The region following the transmembranous domain (in this work indicated as C-
terminal portion), including Aa 113-301 for hSco1p and 79-266 for hSco2p, shows the highest
degree of homology between all known homologues and contains the conserved motif CxxxC
which is essential for ySco1p function [85]. This motif is localised at Aa position 169-173 in
hSco1p and at Aa position 133-137 in hSco2p. Within the C-terminal portion, the two hSco
proteins reach a similarity of 73 %. At the extreme end of the C-terminal domain, the human
homologues differ strongly from the yeast proteins. A PSI-BLAST [201] search made by
Chinenov [176], revealed a low similarity of Sco proteins to bacterial thiol-disulfide
reductases, and a secondary structure predictions using PHD [202] suggests a thioredoxin fold.
Otherwise, the CxxxC motif is reminescent of the copper binding domain of Cox2p .
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3.2 Complementation analysis in yeast of hSco1p and hSco2p
hSco1p and hSco2p were tested for their ability to substitute ySco1p. The respective cDNAs of
the homologues were cloned behind the strong S. cerevisiae ADH1 promoter in the p415 ADH
vector and transformed into strain GR20, which is deleted for ySCO1. Both constructs failed to
restore respiratory competence (Fig. 9, (5) and (6)), i.e. the genes are not per se functional
homologues of ySCO1.
Different chimeric proteins (Fig. 10) were constructed between ySco1p and the human
homologues to identify regions of the human genes which are able to substitute for the
corresponding yeast parts. The chimeras were cloned in the YEp351 vector behind the ySCO1
promoter. To exclude the possibility that the import signal and/or the TM-region of the human
proteins are not functional in S. cerevisiae, chimeras were constructed consisting of the N-
terminal 95 amino acids of ySco1p (including import signal and TM region) and the C-
terminus of hSco1p (ySco1p(1-95)/hSco1p(117-301)) and hSco2p (ySco1p (1-95)/hSco2p(83-
266)), respectively. These constructs, too, proved not to be able to complement the respiratory
deficiency of strain GR20.
In a second set of chimeras the N-terminal 158 amino acids of ySco1p up to the CxxxC-motif
were fused to the C-termini of hSco2p (ySco1p(1-158)/hSco2p(144-266)) and hSco1p
(ySco1p(1-158)/hSco1p(180-301)), respectively. In a control experiment it was shown that the
aminoterminal 158 amino acids of ySco1p (ySco1p(1-158)) alone do not restore respiratory
competence in the Dysco1 strain GR20 [203]. Interestingly the ySco1p(1-158)/hSco1p(180-
301) chimera restored respiratory competence in GR20, while the chimeric protein ySco1p(1-
158)/hSco2p(144-266) did not (Fig. 9, (3) and (4)). Transformants bearing ySco1p(1-
158)/hSco1p(180-301) show a slight cold sensitive phenotype, i.e. a somewhat reduced growth
rate at 23°C as compared to wild type (data not shown). The difference in complementation
behaviour is not due to a proteolytic sensitivity of ySco1p(1-158)/hSco2p(144-266), as a
protein of the expected molecular mass can be detected with ySco1p-antibodies in Western
analysis (data not shown). To test whether parts of the C-terminal region of the human
chromosome 22 homologue may replace the respective yeast sequences, the C-terminal portion
derived from the human homologue was progressively shortened as outlined in Fig. 10:
ySco1p(1-177)/hSco2p(164-266), ySco1p(1-185)/hSco2p (172-266) and ySco1p(1-
222)/hSco2p(209-266). All constructs were transformed into strain GR20 and tested for their
ability to restore respiratory competence. None of the chimeras was able to substitute for
ySco1p function.
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In yeast a truncated version of ySco1p (ySco1p(1-258)), lacking the C-terminal 35 amino
acids, is not functional [203]. Because the extreme C-terminus is one of the most divergent
regions between the homologues it was tested whether the authentic ySco1p C-terminus might
be necessary for function of a chimeric protein. To this end the chimera ySco1p(1-
158)/hSco2p(144-208)/ySco1p(223-295) was constructed. In this protein the aminoterminal
158 amino acids as well as the carboxyterminal 73 amino acids are derived from ySco1p, while
the internal segment corresponds to amino acids 144-208 of hSco2p. This construct, too,
proved not to be functional in yeast.
Fig. 8. 
Fig. 9. Complementation behaviour of Sco1p-derivatives in strain GR20.
Dysco1-strain GR20 was transformed with YEp351 (control (2)) or with plasmids encoding: (1)
ySco1p, (3) ySco1p(1-158)/hSco1p(180-301), (4) ySco1p(1-158)/hSco2p(144-266), (5) hSco1p, (6)
hSco2p. Growth on minimal medium (WO) and glycerol medium (YPGly) was monitored after 3 days
of  incubation at 30°C.
YPGlyWO
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Fig. 10. Overview of constructs tested in the complementation analysis of the Dysco1-strain
GR20.
A. Schematic presentation of ySco1p. B. Schematic presentation of hSco1p and ySco1p/hSco1p
chimeras. C. Schematic presentation of hSco2p and ySco1p/hSco2p chimeras. P indicates the putative
mitochondrial pre-sequence, TM the putative transmembrane domain and CxxxC the potential metal-
binding site. The thin arrow indicates the ySCO1 promoter and the fat arrow the ADH1 promoter.
Sequences derived from ySco1p are in white, from hSco1p in dark grey and from hSco2p in light grey.
Growth of GR20 transformants on YPGly is indicated on the right side: + = growth; - = no growth.
P TM CxxxC
+
C
B
CxxxCTMP
CxxxCTMP
CxxxCTMP
ySco1p(1-95)/hSco1p(117-301)
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3.3 Localisation of hSco1p and hSco2p
The finding that both human Sco proteins by themselves fail to substitute ySco1p function in yeast
raised the question whether the human homologues are located within mitochondria. To examine the
subcellular distribution in vivo, the proteins were fused at the C-terminus to the enhanced green
fluorescent protein (EGFP) and placed behind the cytomegalovirus (CMV) promoter. The
spontaneously fluorescent EGFP protein, an enhanced variant of the GFP protein from the jellyfish
Aequoria victoria, is widely used to facilitate subcellular localisation of a target protein [204]. When
expressed in mammalian cells fluorescence from wild type GFP is typically distributed throughout the
cytoplasm and the nucleus, but excluded from the nucleolus and vesicular organelles [204]. However,
highly specific intracellular localisation including the nucleus, mitochondria, secretory pathway,
plasma membrane and cytoskeleton [205, 206] can be achieved via fusions to individual targeting
sequences. EGFP contains two amino acids substitutions in the chromophore and fluoresces 35-fold
more intensive than wild type GFP. HeLa cells were transfected, using the liposome method, with the
plasmid encoding for EGFP (control), with the plasmid encoding for hSco2p-EGFP and with the
plasmid encoding for hSco1p-EGFP, respectively. After 14 h HeLa cells were analysed with a
fluorescence microscope. Transfectants expressing the hSco1p-EGFP clearly exhibited staining in
punctuated structures (Fig. 11 A). Evidence that these structures represent mitochondria was obtained
by staining with the mitochondria-specific dye MitoTrackerâ Red CMXRos, which resulted in an
identical staining pattern (Fig 11 B). The identity of the patterns was confirmed by overlay of both
fluorescences (Fig. 11 C). In the case of hSco2p-EGFP an identical staining pattern was observed (Fig.
12). In contrast to hSco1p-EGFP, however, occasionally a slight green fluorescence was also detected
in the cytosol, possibly reflecting a higher concentration of the EGFP-fusion protein or a less efficient
mitochondrial import. As expected, HeLa cells transfected with the EGFP-bearing control plasmid
showed an homogeneous green fluorescence which did not correspond to the labeling pattern with
MitoTrackerâ Red CMXRos (data not shown). These data demonstrate that both chimeric hSco-EGFP
proteins are localised in mitochondria and that mitochondrial localisation is mediated by the hSco
portions of the fusion proteins.
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Fig. 11. In vivo localisation of hSco1p.
HeLa cells were transfected with a plasmid encoding for hSco1p-EGFP. After 14 h cells were
counterstained with the mitochondria-specific dye MitoTrackerâ Red CMXRos. A. Green
fluorescence by EGFP. B. Red fluorescence by MitoTrackerâ Red CMXRos. C. Overlay of green
and red fluorescence
Results
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Fig. 12. In vivo localisation of hSco2p.
HeLa cells were transfected with the plasmid encoding for hSco2p-EGFP After 14 h cells were
counterstained with the mitochondria-specific dye MitoTrackerâ Red CMXRos. A. Green
fluorescence by EGFP. B. Red fluorescence by MitoTrackerâ Red CMXRos. C. Overlay of green and
red fluorescence.
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These results were confirmed by Western blot analysis. Because no antisera against hSco1p
and hSco2p were available, C-terminal EGFP-tagged versions of both proteins were used.
EGFP can function as a protein tag, as it tolerates N- and C-terminal fusions to a broad variety
of proteins many of which have been shown to retain native function [204]. The molecular
mass of EGFP is 27 kDa. The expected molecular mass, without the postulated import signal,
is approximately 57 kDa for hSco1p-EGFP and 53 kDa for hSco2p-EGFP. HeLa cells were
transfected with the plasmids encoding for hSco1p-EGFP and for hSco2p-EGFP, respectively.
Mitochondrial and cytosolic fractions were prepared and probed with anti-EGFP antibody.
Cox2p was used as a marker for the mitochondrial fraction. Fig. 13 shows that a band of the
expected molecular mass is localised only in the mitochondrial fraction of hSco1p-EGFP
expressing cells (lane 1) and of hSco2p-EGFP expressing cells (lane 3). The thin bands
observed in both cases above the major bands probably represent the precursor forms. Because
of the high protein expression induced from the CMV promoter, it is possible that not all
proteins are processed to the mature form. This finding would confirm the hypothesis that
hSco1p and hSco2p have a cleavable import sequence. These data are in agreement with the
results of the in vitro import of hSco1p [105].
Fig. 13. Localisation of hSco1p and hSco2p.
Mitochondria (lane 1 and 3) and cytoplasm (lane 2 and 4) of HeLa cells expressing hSco1p-EGFP
(lane 1 and 2) and hSco2p-EGFP (lane 3 and 4) were prepared. Western blot analysis of the two
fractions was done with antibodies against EGFP and Cox2p.
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3.4  Creation of cell lines stably expressing hSco1p-EGFP and hSco2p-EGFP
Transient transfection of cells is time-consuming and expensive. To dispose from a permanent
source of cells expressing hSco1p-EGFP and hSco2p-EGFP, stable cell lines were created.
HeLa cells were transfected with the plasmids encoding for hSco1p-EGFP and hSco2p-EGFP,
respectively, and cells were cultivated under Geneticin selection for five weeks. Single
Geneticin-resistant clones were isolated and allowed to grow for further four weeks. The
resulting cultures were tested for their ability to express the EGFP fusion protein in vivo and by
Western blot analysis. The selection was successful so far only for transfectants expressing
hSco1p-EGFP. One clone, called HeLa 17A3, was isolated which shows a single
mitochondrial band of the expected molecular mass of hSco1p-EGFP in Western blot analysis
(Fig. 14) and a mitochondrial pattern of the EGFP fluorescence in fluorescence microscopic
analysis (Fig. 15). Selection of stable hSco2p-EGFP transfectants was not successful after
three months selection and is still in progress.
Fig. 14. Western blot analysis of the HeLa 17A3 cell line.
HeLa cells were stably transfected with the plasmid encoding for hSco1p-EGFP. Mitochondria (lane 1)
and cytoplasm (lane 2) were probed with the anti-EGFP and the anti-Cox2p antibodies.
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Fig. 15. Fluorescence microscopic analysis of the HeLa 17A3 cell line.
HeLa cells were stably transfected with the plasmid coding for hSco1p-EGFP. Cells were
counterstained with the mitochondria-specific dye MitoTrackerâ Red CMXRos. A. Green
fluorescence by EGFP. B. Red fluorescence by MitoTrackerâ Red CMXRos. C. Overlay of green and
red fluorescence.
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3.5 Functional analysis of hSco1p and hSco2p
All known eukaryotic members of the Sco-protein family possess a single transmembrane
segment, which divides the proteins into a smaller N-terminal segment and a larger C-terminal
segment which bears the essential motif CxxxC. As outlined in the introduction, the CxxxC
motif could be involved in the copper delivery to COX. Sco proteins could mediate this
transfer by direct copper binding or as a thioredoxin which is required for the formation of a
binding-competent 3D-structure of the COX-subunits. To discriminate between the two
models, the C-terminus (Aa 113-301) of hSco1p (hSco1p(C)) and the C-terminus (Aa 79-266)
of hSco2p (hSco2p(C)) were purified and tested for their ability to reduce insulin, a classical
thioredoxin test, and to bind copper. Because the CxxxC motif is essential for the protein
function [85], mutant forms in which both cysteines were replaced by alanines (hSco1pDcys
and hSco2pDcys) were constructed by directed mutagenesis. The C-terminal portions of the
two mutant proteins (hSco1p(C)Dcys and hSco2p(C)Dcys) were then purified for functional
analysis. Because of the difficulty to obtain a membrane protein in its native form, the full-
length proteins have not been purified. Moreover, reductase activity as well as copper binding
have been often proved using only a protein segment bearing the putative functional motif
[156, 157, 207]. The recombinant proteins were isolated from E. coli using affinity
chromatography. Although the folding process is different between the bacterial and the
eukaryotic system, human proteins purified from E. coli often retain their functionality.
Reductase activity was shown for a bacterial-purified mammalian thioredoxin [136] and
copper binding properties have been analysed in bacterial-purified Wilson’s and Menkes
disease proteins [157].
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3.5.1 Affinity purification of the C-terminal portions of hSco1p, hSco2p and of the
mutant hSco forms
The coding regions for hSco2p(C) hSco2p(C)Dcys, hSco1p(C) and hSco1p(C)Dcys were
cloned into plasmid pGEX-4T-3. In the resulting constructs the reading frames of the Sco
proteins are fused in frame to the 3´-end of the GST gene, separated by a sequence which
encodes a thrombin cleavage site. Expression of the fusion proteins under the control of the tac
promoter was induced in E. coli transformants by the addition of IPTG. Steady state
concentrations of the chimeric proteins were monitored at various time points after induction
by SDS-PAGE of cell lysates containing GST-hSco1p and GST-hSco2p and subsequent
Coomassie Blue staining of the gels. Fig. 16 shows the appearance of a band of the expected
molecular weight (48 kDa for both proteins) only after induction with IPTG. Cells were lysed
and insoluble material was removed by centrifugation. Several conditions were tested to
increase the solubility of the recombinant proteins. The solubility increased by lowering the
growth temperature and by induction for a shorter period of time. Moreover several lysis
methods were tested: sonication, freeze/thaw, and french press [190]. The highest protein
yields (1-2 mg protein pro litre culture) were obtained with the latter technique. Lysates of
cells grown at 30° and induced for 30 minutes were used for affinity binding to GSH-
Sepharose. For copper binding analysis, 0,5 mM copper sulphate was added at the beginning
of the induction period. This copper concentration does not affect the growth rate and it was
used in a similar experiment to determine the copper stoichiometry of MNK and WND [157].
Purified fusion proteins bound to GSH-Sepharose were incubated with thrombin to remove the
GST segments. The released hSco2(C) proteins show a molecular mass of 22 kDa, as expected
(Fig. 17). No difference was observed between hSco2p(C) (A) and the mutant form
hSco2p(C)Dcys (B). The recombinant hSco1p(C) and hSco1p(C)Dcys have a molecular mass
of 25 kDa (Fig. 17, C and D), contrary to the expected molecular mass of 22 kDa. To confirm
that the 25 kDa purified segment was not a GST contamination (GST has a molecular mass of
25 kDa after thrombin cleavage), Western blot analysis was performed with anti-GST
antibody. The purified 25 kDa segment was not recognised by the anti-GST antibody (data not
shown). The recombinant hSco1p(C) obviously migrates with an apparent size of 25 kDa on
SDS-polyacrylamide gels. The purity grade of the recombinant proteins were high as deduced
from the Coomassie Blue staining of the gels. This observation was confirmed by gel filtration
analysis (see section 3.6.5).
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Fig. 16. Expression analysis of the C-terminal portions of hSco1p and hSco2p.
BL21 transformants harbouring plasmid pGEX-4T-3 carrying the coding region for Aa 113-301 of
hSco1p (A) and for Aa 79-266 of hSco2p (B) were grown at 30°. The level of protein expression,
before the induction (lane 1), and 30 minutes (lane 2), one hour (lane 3) and two hours (lane 4) after
induction with IPTG, was monitored by SDS-PAGE of cell lysates and subsequent Coomassie Blue
staining of the gels.
Fig. 17. Purification of the C-terminal portions of wild type and mutant forms of hSco2p.
The C-terminal portions of hSco2p (A), hSco2pDCys (B), hSco1p (C) and of hSco1pDCys (D) were
expressed in BL21 and purified by affinity chromatography. Lane 1, supernatant after cell lysis prior to
incubation with GSH. Lane 2, GSH-bound GST-fusion protein. Lane 3, purified protein after cleavage
with thrombin.
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3.5.2 hSco1p(C) and hSco2p(C) have no thioredoxin activity
Thioredoxins catalyse the formation and the reduction of disulfide bonds in proteins. The putative
active sites of hSco1p and hSco2p does not perfectly match those of classical thioredoxins and other
related proteins. However, a predicted thioredoxin fold and the similarity to thiol-disulfide
oxidoreductases, led to the suggestion that Sco proteins could have a catalytic function [176]. To test
whether hSco1p and hSco2p act as a thioredoxin, recombinant hSco2p(C) and hSco1p(C) were
assayed for their ability to reduce disulfide bridges in insulin in the presence of NADPH and
thioredoxin reductase. In this assay, disulfide reductase activity is monitored by increase in the
turbidity of the reaction mixture due to the formation of fine precipitates of dissociated insulin B
chains. In the control, human thioredoxin was used to reduce insulin. Fig. 18 shows that hSco1p(C)
and hSco2p(C) are not active as a disulfide reductase.
Fig. 18. Thioredoxin activity of hSco1p(C) and hSco2p(C).
Human thioredoxin (hThio), hSco1p(C) and hSco2p(C) were tested for their ability to reduce insulin.
Formation of insoluble insulin B chain was followed at 595 nm for 120 minutes.
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3.5.3 Qualitative analysis of copper binding properties of hSco1p(C) and hSco2p(C):
atomic emission analysis
Atomic emission spectroscopy allows the analysis of the metal’s content of a sample. To test if
hSco1p and hSco2p bind copper in vivo, the C-terminal portion of hSco2p and hSco1p was
purified from E. coli grown in medium containing 0,5 mM CuSO4. 60 µg of the purified
protein in PBS-DTT were analysed by atomic emission spectroscopy. Copper-specific
absorption lines at 324,75 nm and 327,40 nm are clearly visible (Fig. 19). Copper lines from
hSco2p(C) are more intensive than from hSco1p(C). However because this method was not
performed in a quantitative manner, the question remains open if the two human homologues
bind copper with different affinities or different stoichiometries. No other metal-specific lines
were present. The absorption lines were less intensive when the protein was isolated from cells
grown in a medium without added CuSO4 (data not shown). This observation suggests that
under normal growth conditions the copper concentration may be too low to load all hSco
proteins with the metal. As negative control PBS-DTT alone and purified GST-Sepharose were
analysed. No copper absorption lines were detected.
To test the requirement of the CxxxC motif for copper-binding, hSco1p(C)Dcys and
hSco2p(C)Dcys were purified as described previously and 60 µg of the protein were analysed
by atomic emission spectroscopy. The two copper-specific signals are detected for hSco2p(C),
however their intensities are dramatically lower as compared to the wild type protein. Copper-
specific signals are detected for hSco1p(C)Dcys, too, if more protein was analysed (data not
shown). This results show that the cysteine residues are involved in copper-binding. The
residual copper binding may indicate the involvement of additional amino acids in the binding
of copper. Copper can require 3 or 4 ligands, and histidine residues in the C-terminal portion of
both proteins could accomplish this function.
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Fig. 19. Atomic emission spectra of wild type and mutant C-terminal portions of hSco1p and
hSco2p.
60 mg of purified C-terminal portions of wild type hSco2p, hSco2pDcys, hSco1p and of hSco1pDcys
were analysed by atomic emission spectroscopy. The spectrum of iron was used as reference and PBS-
DTT and GST-Sepharose were used as negative controls. Wavelengths of the copper-specific lines are
indicated.
3.5.4 Quantitative analysis of copper binding of hSco1p(C) and hSco2p(C): atomic
absorption analysis
To determine the stoichiometry of bound copper in hSco1p and hSco2p in vivo, the C-terminal
portions of hSco1p, hSco2p and hSco2pDcys were purified from E. coli grown in a medium
containing 0,5 mM CuSO4. Bound copper was quantified using atomic absorption
spectroscopy. The graphite furnace atomic absorption was used because it is a very sensible
method which requires only a small amount of sample for the analysis. In the graphite furnace,
the sample is subjected to three heating processes: drying, incineration and atomisation. The
duration and the temperature of these processes have been optimised to obtain the best
signal/noise ratio. The appropriate temperature programme allowed to analyse the native
proteins and to obtain a very good calibration curve in PBS-DTT (Fig. 20). The concentration
of the protein was determined using the Bradford method. This method was preferred to the
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Lowry method because it is not copper-dependent. Protein calibration was performed with
BSA. The protein concentration was calculated from three independent measurements. The
stoichiometry of copper binding was shown to be 1 ± 0,2 µmol of copper per µmol of protein
for hSco2p(C) and 0,2 ± 0,05 µmol of copper per µmol of protein for hSco2p(C)Dcys in three
independent experiments. This result was confirmed by a coupled plasma mass spectrometry
(ICP-MS) analysis performed by Dr. H. Hartel (Department of Chemistry, LMU Munich). The
purified hSco1p(C) contained 0,6 µmol of copper per µmol of protein as determined in a single
experiment. The lower binding capacity of hSco1p(C) compared to hSco2p(C) can reflect a
different copper binding stoichiometry, a different affinity of the two proteins to copper or a
misfolded recombinant hSco1p(C) protein (see Discussion). Recently it was shown that the C-
terminal portion of ySco1p binds copper with a stoichiometry of 1 ± 0,1 µmol copper per µmol
of protein, while the C-terminal portion of ySco1pDcys binds copper with a stoichiometry of
0,15 ± 0,01 µmol copper per µmol of protein [208]. Because a ySco1p/hSco1p chimeric
construct, in which the CxxxC motif was derived from the human protein, can complement the
Dysco1 strain GR20 (see section 3.7.2.1), it can be expected that hSco1p, too, binds copper
with a 1:1 stoichiometry.
Fig. 20. Calibration curve for the atomic absorption analysis.
Calibration was performed using 0,8 µM, 1,4 µM, 2,4 µM, 4 µM and 4,8 µM copper nitrate in PBS-
DTT. Each standard was measured once. Three independent calibration curves were performed.
Results
61
3.6 Interaction analysis of hSco1p and hSco2p
The functional analysis suggests that Sco proteins are mitochondrial copper chaperones. In the
model proposed for yeast, copper is delivered from Cox17p to the Sco proteins in the
mitochondrial intermembrane space. Sco proteins then incorporate the copper into Cox2p [84].
According to this model, an interaction between hSco1p and/or hSco2p with hCox17p and
Cox2p can be postulated. Moreover, dimerisation of copper transporter has been reported for
yCcs [162] and hCcsp [163], and yCox17p forms oligomer complexes [115]. The striking
homology between hSco1p and hSco2p suggests that these two proteins may form an
heteromeric complex, like Sod1p and its chaperone Ccsp [165, 166]. These interactions were
analysed in vitro by affinity chromatography and in some cases in vivo by
coimmunoprecipitation. In the in vitro analysis, one of the proteins is expressed as a GST-
fusion protein, immobilised on GSH-Sepharose and incubated with cell lysate containing the
partner proteins. In the in vivo analysis, one protein is immunoprecipitated from a cell lysate
containing both partner proteins. In the case of an interaction, the partner protein will be found
in the immunoprecipitate. If not specified, both analyses were performed in the presence of 1
mM DTT to avoid unspecific cross-linking by disulfide-bridges. For the analysis of the
dimerisation, gel filtration chromatography was also used. Because no antibodies were
available against hSco1p, hSco2p and hCox17p, epitope-tagged variants were used in both
assays. As epitope tags, EGFP ( see section 3.3) and AU5 were used. AU5 is a 6 Aa peptide
from the bovine papillomavirus type 1 (BPV-1) [192]. Both tags were placed at the C-terminus
of the investigated proteins.
3.6.1 Interaction between hSco proteins and hCox17p
The interaction with hCox17p was tested by affinity chromatography. A C-terminal EGFP-
tagged hCox17p was used in the test. The expected molecular mass for hCox17p-EGFP is 34
kDa. GST-hSco2p(C) (Fig. 21 A), GST-hSco1p(C) (Fig. 21 B) and GST (Fig. 21 C) were
coupled to GSH-Sepharose and incubated with lysate of HeLa-cells expressing hCox17p-
EGFP in the absence of DTT. Sepharose-bound proteins were separated on a 12 % SDS-
PAGE, transferred to PVDF membrane and probed with anti-EGFP antibody. As shown in
lanes 1, hCox17p-EGFP is bound by GST-hSco1p(C) and GST-hSco2p(C), but only a small
amount is bound by GST. The interaction between copper chaperones can be copper-
dependent [151, 154]. To test this eventuality, the GST fusion proteins were loaded with
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copper before incubation with the cell lysate containing hCox17p-EGFP. Lanes 2 show that
hCox17p-EGFP is bound in a copper-dependent manner. If the interaction was performed in
the presence of DTT, almost no interaction could be detected (lanes 3).
Fig. 21. In vitro interaction with hCox17p.
GST-hSco1p(C) (A), GST-hSco2p(C) (B), and GST (C) were bound to GSH-Sepharose and incubated
with cells lysate from HeLa cells expressing hCox17-EGFP. Lane 1: Sepharose-bound proteins were
not loaded with copper. Lane 2: Sepharose bound proteins were loaded with copper. Lane 3: Sepharose
bound proteins were loaded with copper and the interaction was performed in the presence of 1 mM
DTT. Western blot analysis of the precipitates was done with anti-EGFP antibody.
3.6.2 Interaction between hSco proteins and Cox2p
In accordance with the proposed function of Sco proteins as chaperones for the assembly of
Cox2p, an interaction between Sco1p and/or Sco2p with Cox2p can be postulated. This
interaction has been reported for ySco1p [104] and ySco2p [203]. To test this possibility,
affinity chromatography was performed. GST-hSco1p(C) (Fig.22 A, lane 1), GST-hSco2p(C)
(Fig.22 B, lane 1) and GST alone (Fig.22 A, B, lane 2) were coupled to GSH-Sepharose and
incubated with mitochondrial lysate of HeLa cells. Bound material was analysed by Western
blot with anti-Cox2p antibody. No interaction was detected. To test if the interaction is copper-
dependent, GST-hSco1p(C) and GST-hSco2p(C) were loaded with copper before the
incubation with mitochondrial lysate (lanes 3). Again no interaction was detected.
Results
63
Fig. 22. In vitro interaction between hSco1p and Cox2p and between hSco2p and Cox2p.
A. GST-hSco1p(C) (lane 1) or GST-hSco1p(C) loaded with copper (lane3) were bound to GSH-
Sepharose and incubated with mitochondrial lysate of HeLa cells (lane 5). As control GST (lane 2) or
GST loaded with copper (lane 4) were incubated with mitochondrial lysate. B. GST-hSco2p(C) (lane
1) or GST-hSco2p(C) loaded with copper (lane 3) were bound to GSH-Sepharose and incubated with
mitochondrial lysate (lane 5). As control GST (lane 2) or GST loaded with copper (lane 4) were
incubated with mitochondrial lysate. Western blot analysis was performed with anti-Cox2p antibody.
The interaction with Cox2p was tested also with coimmunoprecipitation. hSco1p-EGFP and
hSco2p-EGFP were immunoprecipitated with anti-EGFP antibody from lysate of HeLa cells
expressing the two EGFP fusion constructs, respectively. As a negative control,
immunoprecipitation with anti-EGFP antibody was performed from lysate of HeLa cells
expressing EGFP alone. Immunoprecipitates were analysed with anti-Cox2p antibody. Fig. 23
shows that a weak Cox2p band was detected only in the precipitate of hSco1p-EGFP-
expressing cells (lane 2) but not in hSco2p-EGFP-expressing cells (lane 3) or in the control
(lane 4)
Fig. 23. Coimmunoprecipitation of hSco1p, hSco2p and Cox2p.
Mitochondrial lysate from HeLa cells expressing hSco1p-EGFP (lane 2), hSco2p-EGFP (lane 3) or
EGFP (lane 4) was immunoprecipitated with anti-EGFP antibody. In lane 1 mitochondrial lysate of
untransfected HeLa cells was loaded. Western blot analysis of the precipitates was done with anti-
Cox2p antibody.
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3.6.3 Homomerisation of hSco1p and hSco2p
The ability of the C-terminal segment of hSco1p and hSco2p to form homomeric complexes
was tested by affinity chromatography. hSco2p(C) fused to GST was coupled to GSH-
Sepharose and incubated with cell lysate of HeLa transformants expressing a hSco2p-EGFP
fusion protein. Sepharose-bound material was analyzed in Western blot with antibody against
EGFP. Fig. 24 A shows that hSco2p-EGFP is bound to GST-hSco2p(C)-Sepharose (lane 1),
but not to GST-Sepharose (lane 3). In a further control, Sepharose-bound GST-hSco2p(C) was
incubated with cell lysates containing EGFP. Again no binding was observed (data not shown).
Similar results were obtained if GST-hSco1p(C) was incubated with lysate of Hela cells
expressing hSco1p-EGFP (Fig. 24 B). hSco1p-EGFP is bound by GST-hSco1p(C) (lane 1), but
not by GST alone (lane 3).
To test whether the CxxxC motif is required for homomerisation, GST-hSco1p(C) and GST-
hSco2p(C) were bound to Sepharose and incubated with hSco1pDcys-EGFP (Fig. 24 A, lane 2)
and hSco2pDcys-EGFP, respectively (Fig. 24 B, lane 2). The results show that the interaction
does not depend on the CxxxC motif.
Fig. 24. Homomerisation of hSco2p and hSco1p.
A. GST-hSco2p(C) was bound to GSH-Sepharose and incubated with lysate of HeLa cells expressing
hSco2p-EGFP (lane 1) or hSco2pDcys-EGFP (lane 2). In lane 3, GST was bound to GSH-Sepharose
and incubated with lysate of HeLa cells expressing hSco2p-EGFP. B. GST-hSco1p(C) was bound to
GSH-Sepharose and incubated with lysate of HeLa cells expressing hSco1p-EGFP (lane 1) or
hSco1pDcys-EGFP (lane 2). In lane 3, GST was bound to GSH-Sepharose and incubated with lysate of
HeLa cells expressing hSco1p-EGFP. Western blot analysis of the precipitates was done with anti-
EGFP antibody.
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3.6.4 Heterodimerisation between hSco1p and hSco2p
The interaction between hSco1p and hSco2p was tested by affinity chromatography and by
immunoprecipitation. In the first test, GST-hSco2p(C) was coupled to GSH-Sepharose and
incubated with lysate of HeLa cells expressing hSco1p-EGFP (Fig. 25, lane 1). In a parallel
experiment, GST-hSco1p(C) was coupled to GSH-Sepharose and incubated with lysate of cells
expressing hSco2p-EGFP (Fig. 25, lane 2). Sepharose-bound proteins were analysed by
immunoblotting with anti-EGFP antibody. The results show that hSco1p and hSco2p are able
to interact in vitro.
Fig. 25. Interaction between hSco1p and hSco2p.
hSco2p-GST was coupled to GSH-Sepharose and incubated with lysate of HeLa cells expressing
hSco1p-EGFP (lane 1). hSco1p-GST was coupled to GSH-Sepharose and incubated with lysate of
cells expressing hSco2p-EGFP (lane 2). Western blot analysis of the precipitates was performed with
anti-EGFP antibody.
This result was confirmed by coimmunoprecipitation. hSco1p-AU5 was immunoprecipitated
with anti-AU5 antibody from lysate of HeLa cells expressing hSco1p-AU5 and hSco2p-EGFP.
As negative control, immunoprecipitation with anti-AU5 antibody was performed from HeLa
cells lysate containing only hSco2p-EGFP. Immunoprecipitate was analysed with antibody
against EGFP produced in rabbit to avoid the detection of the light and heavy chain of the AU5
antibody. Fig. 26 shows that the hSco2p-EGFP band was detected in the precipitate of hSco1p-
AU5 expressing cells (lane 1), but not in the control (lane 2).
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Fig. 26. Coimmunoprecipitation of hSco1p and hSco2p.
Cell lysate containing hSco1p-AU5 and hSco2p-EGFP (lane 1) or hSco2p-EGFP (lane 2) was
immunoprecipitated with anti-AU5 antibody. Western blot analysis of the precipitates was done with
anti-EGFP antibody.
.
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3.6.5 FPLC analysis of hSco1p(C) and hSco2p(C)
The ability of the C-terminal portion of hSco1p(C) and hSco2p(C) to form dimers was also
tested with analytical gel filtration. hSco1p(C) and hSco2p(C) were affinity-purified as
described in section 3.5.1 and 500 µg purified proteins were loaded on a Sephadex 75 HR
10/30 column. Proteins were eluted in PBS-DTT at room temperature. The most part of
hSco2p(C) elutes as a monomer, hSco1p(C) elutes as a 1:1 mixture of the monomeric and
dimeric form (Fig. 27). No other proteins peaks have been detected, confirming the high purity
of the affinity-purified proteins. As molecular mass marker, carbonic anhydrase (29 kDa) and
BSA (66 kDa) were used.
Fig. 27. Elution profile of hSco1p(C) and hSco2p(C) on gel filtration column.
hSco2p(C) and hSco1p(C) were chromatographed in PBS-DTT under the same conditions. The
column was calibrated with molecular weight standards (MW) of 66 kDa and 29 kDa.
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3.7 Characterisation of pathogenic mutant proteins
The yeast system offers a wide spectrum of molecular genetic manipulation and has been
repeatedly used for analysing human mutations [40, 80, 81, 92]. Because the hSCO2 gene can
not substitute for the ySCO1 gene and the deletion of the ySCO2 gene does not result in a
phenotype, information about the role of the hSco2p mutations can be deduced only indirectly
from the yeast model for example by introducing the mutations in ySco1p [92]. To characterise
the role of the hSco2p mutations, analyses in HeLa cells and with the purified mutant proteins
were performed. hSco1p can substitute ySco1p in chimeras and the yeast model was used to
test the effect of the reported mutation on COX assembly.
3.7.1 Characterisation of pathogenic hSco2 mutant proteins
Compound heterozygotes for mutations in hSCO2 suffer from a fatal form of
cardioencephalomyopathy [95, 109, 110]. Three point mutations have been identified so far. In
this work, attention was focused on the E140K mutation and on the S225F mutation. In the
yeast system only one of the two missense mutations (S225F), introduced in ySco1p, had a
strong effect on COX-activity and COX-assembly, while the other (E140K) did not impair
COX-activity [92]. To elucidate the mechanisms, by which the two mutations affect the
function of hSco2p, the intracellular localisation, the copper binding and the homomerisation
were analysed. The mutations were introduced into hSCO2 by site-directed mutagenesis. C-
terminal-EGFP tagged versions of the two mutant proteins were created. The C-terminal
portions (Aa 79-266) of hSco2p(E140K) (hSco2p(C)(E140K)) and hSco2p(S225F)
(hSco2p(C)(S225F)) were purified as described for the wild type hSco2p(C). Fig. 28 shows
that a fragment of the expected molecular mass of 22 kDa was obtained, like the wild type
hSco2p(C) (see section 3.5.1). The amount of purified hSco2p(C)(E140K) was somewhat
reduced (Fig. 28 A). This can hint at an effect of the mutation on the stability of the protein.
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Fig. 28. Purification of the C-terminal portions of mutant hSco2 proteins.
hSco2p(C)(E140K) (A) and hSco2p(C)(S225F) (B) were expressed in BL21 and purified by affinity
chromatography. Lane 1, supernatant after cell lysis prior to incubation with GSH. Lane 2, GSH-
Sepharose bound GST-fusion protein. Lane 3, purified protein after cleavage with thrombin.
3.7.1.1 Mutant proteins localise to mitochondria
HeLa cells expressing hSco2p(E140K)-EGFP (Fig. 29) or hSco2p(S225F)-EGFP (Fig. 30)
were analysed by fluorescence microscopy. Both mutant proteins are targeted to mitochondria
as revealed by counterstaining with the mitochondria-specific stain MitoTrackerâ Red
CMXRos. Therefore, mislocalisation due to the mutations can be excluded. The localisation
was confirmed by Western blot analysis. Mitochondrial and cytosolic fractions of HeLa cells
expressing hSco2p(E140K)-EGFP or hSco2p(S225F)-EGFP were prepared and probed with
anti-EGFP and anti-Cox2p antibodies. A band of the expected molecular mass was observed
only in the mitochondrial fraction of both constructs (data not shown).
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Fig. 29. Intracellular localisation of hSco2p(E140K)-EGFP.
The coding region of hSco2p(E140K) was fused to EGFP, the resulting plasmid transfected into HeLa
cells, and transfectants were visualised by fluorescence microscopy. Mitochondria were counterstained
with MitoTrackerâ Red CMXRos. A. Green fluorescence. B. Red fluorescence. C. Overlay of green
and red fluorescence.
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Fig. 30. Intracellular localisation of hSco2p(S225F)-EGFP.
The coding region of hSco2p(S225F), was fused to EGFP, the resulting plasmid transfected into HeLa
cells, and tranfectants were visualised by fluorescence microscopy. Mitochondria were counterstained
with MitoTrackerâ Red CMXRos. A. Green fluorescence. B. Red fluorescence. C. Overlay of green
and red fluorescence.
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3.7.1.2 Copper binding of mutant proteins
One of the mutations, E140K, is located next to the metal-binding motif. The other mutation,
S225F, is located next to a conserved histidine which was discussed as copper binding site
[179] and which was shown to be essential for the protein function [104, 179]. Purified
hSco2p(E140K)(C) and hSco2p(S225F)(C) from E. coli grown in 0,5 mM CuSO4 were
subjected to atomic emission spectroscopy. Fig. 31 shows that both mutant proteins are still
able to bind copper. However the exact stoichiometry of the bound copper has still to be
analysed.
Fig. 31. Atomic emission spectrum of the C-terminal portions of hSco2p mutants.
60 mg of purified C-terminal portions of hSco2p(S225F) and of hSco2p(E140K) were
analysed by atomic emission spectroscopy. The spectrum of iron was used as reference.
Wavelengths of the copper-specific lines are indicated.
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3.7.1.3 Mutant proteins can homomerise
The mutant proteins were also tested for their ability to homomerise. The C-terminal segments
of hSco2p(E140K) (Fig 32 A, lane 1) and hSco2p(S225F) (Fig 32 A, lane 2) were bound as
GST-fusions to GSH-Sepharose and tested for interaction with hSco2p-EGFP. In a parallel
assay wild type hSco2p(C)-GST was coupled to GSH-Sepharose and tested for binding to
hSco2p(E140K)-EGFP (Fig 32 B, lane 1) and to hSco2p(S225F)-EGFP (Fig 32 B, lane 2).
Both mutant proteins are able to form homomeric complexes. This result shows that the
mutations do not affect the homomerisation.
To mimic the situation in patients, who present with two independent hSCO2 mutant alleles,
the interaction between hSco2p(E140K) and hSco2p(S225F) was determined using GST-
hSco2p(C)(S225F) and hSco2p(E140K)-EGFP (Fig. 32 B, lane 3). Again the formation of
homomeric complexes by the mutant proteins was observed.
Fig. 32. Homomerisation of hSco2 mutant proteins.
A. GST-hSco2p(C)(E140K) (lane 1) and GST-hSco2p(C)(S225F) (lane 2), were bound to GSH-
Sepharose and incubated with lysate of HeLa cells expressing hSco2p-EGFP. B. GST-hSco2p(C) was
bound to GSH-Sepharose beads and incubated with lysate of HeLa cells expressing hSco2p(E140K)-
EGFP (lane 1) and hSco2p(S225F)-EGFP (lane 2). In lane 3, GST-hSco2p(C)(S225F) was bound to
GSH-Sepharose and incubated with lysate of HeLa cells expressing hSco2p(E140K)-EGFP.
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3.7.2 Characterisation of the pathogenic hSco1p mutant
Recently it was reported that mutations in the hSCO1 gene may result in COX-deficiency. A
substitution of proline at position 174 by leucine (P174L) was detected in compound
heterozygous patients suffering from hepatic failure and ketoacidotic coma [108]. However,
direct experimental proof for the pathogenicity of this mutation was lacking. Because the
authentic human gene is not capable to complement a Dysco1 strain, yeast/human chimeric
constructs were used to test the effect of this mutation on mitochondrial function in yeast. To
this purpose, two novel chimeric proteins were created. In both proteins the C-terminal portion
derived from hSco1p included the CxxxC motif.
3.7.2.1 Complementation of yeast/human Sco1p chimeras K1 and K2
Two novel chimeric SCO1 genes which differ in the carboxyl-terminal portion derived from
the human hSCO1 gene were constructed and cloned in YEp351 behind the ySCO1 promoter
(Fig. 33). In chimera K1 (ySco1p(1-134)/hSco1p(156-301)) the human portion comprises 145
amino acids, while in chimera K2 (ySco1p(1-117)/hSco1p(139-301)) 162 amino acids stem
from the human protein. In both chimeric proteins the conserved CxxxC-motif is derived from
hSco1p. Each of the proteins was expressed in the respiratory deficient Dysco1 strain GR20
and the transformants were tested for their ability to grow on the non-fermentable carbon
source glycerol at three temperatures (23°C, 30°C, 37°C) (Fig. 34). K2-transformants show a
faint cold-sensitive phenotype: at 30°C and 37°C they grow like wild type cells, while their
growth is somewhat reduced at 23°C. K1-transformants exhibit a strong temperature-sensitive
effect, they grow only at 30°C. Addition of 0.2 % copper sulphate to YPEG plates resulted in a
wild type-like growth of all transformants at all temperatures (Fig. 34).
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Fig. 33. Yeast/human Sco1p chimeras created to test the effect of the P174L mutation.
The arrow indicates the ySCO1 promoter, mTS the mitochondrial presequence, TM the transmembrane
domain, CPDVC the potential metal-binding site. Mutated amino acids are shown in Italics. Sequences
derived from ySco1p are given in white, those from hSco1p in dark. Growth of GR20 transformants on
YPGly or YPGly supplemented with 0,2 % CuSO4 (+ Cu) at 30° are indicated on the right: + = growth,
- = no growth.
Fig. 34. Effect of the P174L mutation on the complementation behaviour of yeast/human Sco1p
constructs in strain GR20.
Dysco1 strain GR20 was transformed with YEp351 (2) or with plasmids encoding ySco1p (1), K1 (3),
K1L (4), K2 (5) or K2L (6). Growth on minimal medium (WO) and glycerol medium (YPGly) or
glycerol medium supplemented with 0,2 % CuSO4 (YPGly + Cu
2+) was monitored after 3 days
incubation at the indicated temperatures.
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3.7.2.2 The P174L mutation impairs the function of the chimeras K1 and K2
The P174L mutation was introduced into chimeras K1 and K2 with directed mutagenesis. The
resulting mutant chimeras K1L and K2L, respectively, were expressed in strain GR20 and the
transformants were tested for their respiratory competence at 23°C, 30°C and 37°C (Fig. 34,
(4) and (6)). All transformants failed to grow on glycerol medium, indicating that the mutant
Sco-proteins are non-functional. Addition of copper sulphate to the YPGly plates resulted in a
wild-type like growth of K2L-transformants, whereas K1L-transformants still failed to grow.
These data show, that the P174L mutation is pathogenic in the yeast model and strongly
suggest that this mutational alteration may also be refractive for the function of the human
hSco1p.
To test whether the pathogenic nature of the mutation results from an instability of the mutant
proteins, mitochondria from the respective transformants were analysed for the presence of the
chimeric proteins. As shown in Fig. 35 all chimeric proteins are present in comparable
concentrations with the exception of construct K1L, the quantity of which is somewhat
reduced (lane 4). It seems unlikely that this reduction in the concentration can account for the
complete loss of function. Therefore, the inability of the mutant proteins to complement strain
GR20 does not result from instability, but rather from an impaired function.
Fig. 35. Influence of the P174L mutation on COX assembly.
10 µg of mitochondrial proteins were separated on a 12 % polyacrylamide gel, transferred to
PVDF membrane and probed with antibodies directed against ySco1p, Cox1p and Cox2p. The
Dysco1 strain GR20 was transformed with the vector YEp351 (lane 2) or with plasmids encoding
ySco1p (lane 1), K1 (lane 3), K1L (lane 4), K2 (lane 5) or K2L ( lane 6).
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3.7.2.3 COX assembly is disturbed in strain GR20 expressing chimeras K1L or K2L
As described in the Introduction, lack of ySco1p results in the preferential degradation of
unassembled subunits Cox1p and Cox2p. The concentration of these subunits was determined
in GR20 cells, which express chimeras K1L or K2L. Mitochondria obtained from GR20 cells,
transformed with K1, K1L, K2, or K2L were analysed with antibodies directed against Cox1p
or Cox2p. As shown in Fig. 35, there is a very good correlation between the steady state
concentration of Cox1p and Cox2p and the COX activity: in K1- and K2-transformants both
subunits are present in concentrations similar to those of wild type cells (lanes 3 and 5). By
contrast, the two COX-subunits are almost completely absent in K1L-transformants (lane 4) or
only present in trace amounts in K2L-transformants (lane 6).
3.7.2.4 COX activity is affected by the P174L mutation
Mitochondria were prepared from strain GR20, expressing chimeras K1, K1L, K2, or K2L,
and assayed for COX activity as described in Material and Methods. Fig. 36 summarises the
results. As expected there is almost no COX-activity in the Dysco1 strain GR20 (1,5 % of wild
type activity, lane 2). After expression of chimeras K1 or K2, the COX-activities are 55 %
(lane 3) and 85 % (lane 5), respectively, of the wild type activity. These data correlate well
with the growth characteristics of the transformants on YPGly: growth of K2-transformants on
YPGly is almost indistinguishable from that of wild type cells, while growth of K1-
transformants is more severely affected. Expression of the chimeric proteins with the P174L
mutation results in a dramatic reduction of COX activity to 2,5 %  in the case of K1L (lane 4)
and to 30 % in the case of K2L (lane 6). Again these data correlate well with the growth
phenotype of the transformants on YPGly.
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Fig. 36. COX activity in strains expressing wild type ySco1p or ySco1p/hSco1p chimeras.
Mitochondria were isolated and cytochrome c oxidase activity was determined. Activities are mean values of
several independent experiments and are normalized to the value obtained for the transformant
expressing wild type ySco1p (= 200 nmol cytochrome c oxidised/min/mg  mitochondrial protein). The
Dysco1 strain GR20 was transformed with the vector YEp351 (lane 2, negative control) or with
plasmids encoding ySco1p (lane 1, positive control), K1 (lane 3), K1L (lane 4), K2 (lane 5) or K2L
(lane 6).
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4 DISCUSSION
4.1 Structural analysis and localisation of hSco proteins
hSco1p and hSco2p belong to the family of Sco proteins, conserved from prokaryotes to
eukaryotes. The best characterised Sco proteins are from the yeast Saccharomyces cerevisiae.
ySco1p has a tripartite structure with a single transmembrane segment (TM) which anchors the
protein in the inner mitochondrial membrane (IM), a minor aminoterminal part, which is
oriented to the mitochondrial matrix [103], and a major carboxylterminal part, which is
exposed to the mitochondrial intermembrane space (IMS) and which carries the conserved
CxxxC motif. The structure of both human proteins is similar to that of the yeast protein.
Computer analysis predicts a N-terminal import signal and a transmembrane domain, the
CxxxC motif is present. The mitochondrial localisation of both human proteins was
demonstrated in this work by two methods. hSCO1 and hSCO2 were fused C-terminally with
EGFP and the localisation of the resulting fusion proteins was observed in vivo in HeLa cells
with fluorescence microscopy. In both cases the EGFP-fluorescence pattern hints at a
mitochondrial localisation, because it is the same as in the cells stained with a mitochondria-
specific dye. Western blot analysis of the EGFP-fusion proteins confirms the mitochondrial
localisation and hints at the existence of a cleavable import sequence. N-terminal cleavable
mitochondrial targeting sequences (MTS) represent the most common form of mitochondrial
protein import [209]. Other arrangements, however, have been described recently. The
mitochondrial DNA-helicase Hmi1p has a cleavable carboxyl-terminal targeting sequence
[210]. Bcs1p does not contain a N-terminal targeting sequence. A positively charged segment
of amino acids which is located immediately C-terminal to the transmembrane domain acts as
an internal targeting signal. This sequence co-operates with the transmembrane domain to form
a tight hairpin loop structure which is translocated across the inner membrane. This mechanism
of import and sorting of Bcs1p is proposed to represent a more general mechanism used by a
number of inner membrane proteins [211]. Interestingly a similar cluster of positive residues is
present in Sco proteins and it was shown that ySco1p without the putative N-terminal MTS is
still imported in mitochondria [203]. Moreover, this region was shown to be important for the
protein structure [203]. It cannot be excluded that the import of Sco proteins involves the
presence of two sorting informations. The cleavable N-terminal presequence therefore would
not be essential, but it would enhance the specificity and/or efficiency of import. This
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possibility was discussed for the phosphate carrier of mammalian mitochondria [212].
Preliminary experiments using the C-terminal portion of hSco proteins suggest that the human
homologues can also be imported in the mitochondria without the N-terminal import signal
(data not shown).
The involvement of Sco proteins in the COX deficiency suggests that both proteins are
localised in the inner membrane. This localisation was demonstrated so far only for ySco1p
[103]. In this case it was also shown that the C-terminal portion of the protein is oriented to the
IMS [100]. The importance of the orientation of the protein will be discussed later.
4.2 Complementation analysis in yeast
The ability of hSco proteins to substitute for the yeast homologue was tested in the Dysco1
strain GR20. The human proteins are per se not able to complement the GR20 strain.
Therefore, either the hSco proteins are not functional homologues or some parts of the yeast
protein cannot be replaced from their human counterparts. The N-terminal portion is the most
divergent between the Sco homologues. To exclude the possibility that differences in the
import machinery between yeast and human led to a mislocalisation of the human constructs in
yeast, chimeras were created in which the N-terminal portion and the TM domain were derived
from the yeast protein (ySco1p(1-95)/hSco1p(117-301) and ySco1p(1-95)/hSco2p(83-266)).
These constructs, too, were not able to complement the GR20 strain. Because the region
around the TM was shown to be important for the protein structure [203], further chimeras
were created. A construct in which the N-terminal portion, the TM domain, and a part of the C-
terminal portion up to the CxxxC motif was derived from ySco1p and the remaining C-
terminal portion from hSco1p (ySco1p(1-158)/hSco1p(180-301)) was able to complement.
This result suggests that the protein stretch between the TM and the CxxxC motif,
encompassing about 60 amino acids, is critical for function in yeast and must - at least in part -
be derived from the authentic yeast protein. This idea is supported from studies on ySco1p and
ySco2p chimeras [203]. The finding that two novel chimeras, K1 (ySco1p(1-134)/hSco1p(156-
301)) and K2 (ySco1p(1-117)/hSco1p(139-301)), in which the C-terminal portion derived from
hSco1p was progressively increased, are functional in yeast, allows the restriction of this
critical region to a stretch of about 20 amino acids. Possibly this protein part is involved in
protein-protein interactions or it is required for the correct steric positioning of functionally
important amino acids. Alternatively this part may be involved in protein import as discussed
above. Whatever the function of this segment may be, it obviously cannot be provided by the
Discussion
81
homologous stretch of hSco1p. Interestingly, chimera K2, in which the hSco1p-derived portion
is larger than in chimera K1, seems to be more functional as suggested by the higher COX-
activity and the growth characteristic of the respective transformants. This observation may
hint at a domain structure of the C-terminal portion of the Sco proteins. Perhaps, formation of a
functional three-dimensional structure is favoured, if most or all amino acids of such a domain
originate from a single protein. This interpretation is supported by the temperature-sensitive
growth phenotype of K1-transformants on YPGly, which may hint at the inability of the
protein to correctly fold at 23°C and 37°C, respectively.
Interestingly, in this work no chimeras between ySco1p and hSco2p were found which could
suppress the respiratory deficiency of the GR20 strain. Although it cannot be excluded that
improper folding of the chimeras interferes with their function in yeast, these data favour the
idea that the chromosome 17 homologue, hSco1p, represents the functional ySco1p
homologue. The chromosome 22 homologue, hSco2p, could represent the homologue of
ySco2p. This result is in agreement with the actual nomenclature proposed by Papadopoulou et
al. (1999) [95]. Because a Dysco2 strain does not show any mutant phenotype [84], it is not
possible to test if hSco2p can substitute for ySco2p. Even if hSco2p represents the homologue
of ySco2p, it would be expected that a chimera exists which can complement the GR20 strain,
as is the case for ySco1p/ySco2p chimeras [203].
Yeast has often been used as a model to analyse human mutations. Yeast provides special
advantages for studying mitochondrial proteins because – as a facultative anaerobe - it can
grow on fermentable media if the respiratory chain is deficient. Mutations in various mt
proteins found by sequencing DNA from patients have been engineered in the corresponding
yeast genes to assess the functionality of the mutant proteins. For example, the pathogenic
nature of the N204K mutation in Cox10p was confirmed in this way [80]. Yeast strains with
mutations in the hSURF1 homologue ySHY1 display inadequate electron transfer between
COX and other components of the respiratory chain [81]. Recently complementation study in
yeast confirmed the deleterious effect of mutations in hBCS1L, a nuclear gene involved in the
assembly of complex III [40]. Despite the fact that hSco2p is not a functional homologue of
ySco1p, the yeast system can be used to obtain valuable information on the effect of mutations
detected in patients. Dickinson et al. [92] described the effect of the S225F mutation of hSCO2
on COX-assembly, when introduced into the homologous ySCO1 gene. In this work, the yeast
system was chosen to analyse the effect of a hSco1p mutation. A substitution of proline at
position 174 by a leucine was recently detected in compound heterozygous patients suffering
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from hepatic failure and ketoacidotic coma [108]. However, direct experimental proof of the
pathogenicity of this mutation was lacking. Because the authentic human gene is not capable
of complementing the Dysco1 strain, the K1 and K2 yeast/human chimeric constructs, in which
the CxxxC motif is provided by the human homologue, were used to test the effect of this
mutation on mitochondrial function in yeast. The P174L mutation was introduced into
chimeras K1 and K2 with directed mutagenesis. The resulting mutant chimeras K1L and K2L
documented that the P174L mutation severely affects the function of the protein in the
assembly of COX. A dramatic reduction in the content of subunits Cox1p and Cox2p, which
are known to be susceptible to degradation in case of incorrect assembly [102, 106], was
observed. Concomitantly the COX-activity was severely reduced. Interestingly, the effect was
less pronounced in transformants expressing chimera K2L: their COX-activity was about 30 %
of wild-type activity and in line with this observation residual levels of Cox1p and Cox2p
could be detected. This suggests that the mutant protein has retained some of its function. The
possible role of this mutation will be discussed later.
4.3 Functional analysis of hSco proteins
ySco1p is essential for mitochondrial respiration. A Dysco1 strain is respiration deficient and
spectroscopic analysis shows a selective reduction of cytochrome a and a3, [92] which are
localised in COX. Western blot analysis of the COX complexes shows a specific reduction of
Cox1p and Cox2p while the other subunits are less affected [102]. The ability of the Dysco1
strain to synthesise the mitochondrial encoded subunits of COX and to accumulate the
nuclearly encoded subunits suggests that ySco1p is involved in the assembly pathway [100,
107]. Mutations in the two corresponding human genes also cause severe COX deficiencies.
Immunohistochemistry shows a specific reduction of Cox1p and Cox2p in hSCO2 patients
[95]. Besides, the data from this work showed that mutations in hSco1p, if engineered in
yeast/human chimeras, lead to a reduction of Cox1p and Cox2p. Therefore, it seems likely that
assembly of Cox1p and Cox2p is affected.
Both subunits carry the prosthetic groups essential for COX activity. Cox2p carries two copper
ions, Cox1p carries heme a and a3 and a copper ion. The assembly of the heme centre requires
Cox10p [118] and mutations in this gene have been detected in patients suffering from
tubulopathy and leukodystrophy [80]. Sco proteins are probably not involved in the assembly
of the heme centre. This can be deduced from the finding that in yeast, a specific ySCO1
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mutation leads to a partially assembled COX complex lacking only Cox2p, but showing the
absorption bands typical of the heme centres [92].
Since Cox1p and Cox2p are synthesised inside the mitochondria, the 3 copper atoms have to
be imported from the cytoplasm. As underlined in the introduction, different evidences
implicate that Sco proteins are involved in the assembly of copper centre. Overexpression of
ySco1p can compensate for the loss of yCox17p, which acts as a copper shuttle between the
cytosol and the mitochondrial intermembrane space [84]. Suppression of a ycox17 deletion by
over-expression of ySCO1 is more efficient in the presence of an elevated concentration of
copper ions in the growth medium [84]. Overexpression of ySCO2 can also complement the
Dycox17 strain, but only in the presence of higher amount of copper. Furthermore, it has been
shown in this work that the chimeric construct between ySco1p and hSco1p carrying the
P174L mutation can be rescued by addition of copper to YPGly plates. Therefore, Sco proteins
are possibly involved in the transfer of copper ions to COX, and COX-subunits lacking copper
cannot be correctly assembled and are degraded. Importance of copper in the COX assembly is
confirmed by the observation of a decrease of COX level in heart mitochondria of copper-
deficient rats, due to a diminished content of assembled protein [213].
Sco proteins could act either as copper chaperones by binding copper and transferring it to
COX or as thioredoxins, required to maintain the cysteine residues of the copper binding site in
a reduced state. This last function can be postulated only for the CuA centre: the two copper
atoms of the CuA centre are coordinated by two His, one Met, a backbone carbonyl oxygen of
Glu, and two bridging Cys residues, while CuB is bonded by three His and a Tyr. A schematic
representation of both models is given in fig 37.
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Fig. 37. Two models for the function of Sco proteins.
Sco proteins are involved in the insertion of copper in COX. Sco proteins could perform this function
in two ways. In the upper picture, Sco proteins are shown as copper chaperones which acquire copper
for example from Cox17p and transfer it to COX. In the lower picture, Sco proteins are shown as
thioredoxins which reduce the disulfide bonds of the metal binding motif of COX, permitting the
insertion of copper from Cox17p.
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4.3.1 hSco proteins bind copper
To fulfil the role of copper chaperones, Sco proteins must be able to bind copper. In this work
it has been shown that hSco2p and hSco1p bind copper with two different analyses, the atom
emission spectroscopy and the atom absorption spectroscopy. To analyse copper binding, the
C-terminal portions of both proteins were purified with affinity chromatography in PBS-DTT
by using the GST system. The reducing condition was chosen to assure the specificity of
copper binding. In the case of hCcsp it was shown that the protein contains copper sites in
excess in an aerobic (oxidising) environment but approaches the expected ratio of 2 coppers
per protein under reducing conditions [164]. Proteins derived from a further purification step
with gel exclusion chromatography were not used for the analysis because it was observed that
multiple purification steps reduce the metal content of the protein. The atomic emission
spectroscopy performed in this work shows that hSco proteins specifically bind copper. No
other metals could be identified in the proteins purified from bacteria grown without addition
of copper in the medium. To determine metal binding specificity of hSco proteins other
methods could be used, like metal-chelate chromatography on resin equilibrated with different
heavy metals [48]. The specific affinity for copper reflects the inability of the metal binding
site of the domain to conform to the preferred ligation geometry of other metals. Treatment of
the fusion protein, eluted from the glutathione affinity column in the absence of DTT, with the
Cu(I) specific chelator BCS gives an orange colour indicative of the Cu(I)(BCS)2
- complex
(data not shown). This suggests that copper is bound in the +1 oxidation state. The +1
oxidation state of copper has been so far described for all copper chaperones.
With the atomic absorption analysis hSco2p was shown to bind copper with a stoichiometry of
1:1 (copper : protein) and hSco1p with a stoichiometry of 0,6:1 (copper : protein). The putative
copper binding site CxxxC is present only once and a 1:1 stoichiometry is expected for both
proteins. Other copper chaperones like hHah1p and yAtx1p contain one copper binding motif
CxxC and were shown to bind one copper ion. WND and MNK contain each six copper
binding motif and bind 6 copper ions.
The lower copper binding of hSco1p can have different reasons. First, it is possible that
hSco1p binds copper as a dimer, with one copper ion bound by four cysteines. The FPLC
analysis shows that the C-terminal portion of hSco1p exists as a mixture of monomers and
dimers. In this work the copper content was measured without separating the monomer form
from the dimer form. Second, the affinity of hSco1p to copper can be lower than that of
hSco2p and copper can be lost during the purification procedure. The fact that copper is lost by
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multiple purification steps suggests that copper is not tightly bound. The affinity of copper
proteins to the metal is different and it depends on the protein’s function. Metallothioneins
(MT) have a very high affinity for copper. A weaker bond can be necessary to allow copper to
be released and transferred to other proteins. Interestingly, affinity of copper binding can
depend on the copper concentration in the cell. MNK has a low affinity for copper at low
copper concentration, by increasing the copper concentration the affinity increases [214]. Thus,
addition of a higher copper concentration in the E. coli medium, before induction with IPTG,
could eventually result in an increase of bound copper in hSco1p. Third, it is possible that the
bacterial system used in the purification led to an altered protein fold with subsequent loss of
bound copper. Lutsenko et al. (1997) pointed to the importance of the three-dimensional
structure of the MNK and WND metal binding motifs for selectivity toward copper [215]. The
bacterial cytoplasm is known to be more reducing than its eukaryotic counterpart and thus it is
not an ideal environment for the production of properly folded eukaryotic proteins. In the case
of the purification of the MNK protein, a 0,0026 : 1 (Cu : protein) stoichiometry instead of the
expected 1 : 1 was found. To overcome this problem and to obtain a functional protein, a new
approach was reported [216] which required cotransfection of E. coli with a thioredoxin-
encoding plasmid. The expression of high levels of thioredoxin seems to change the redox
potential of E. coli cells, mimicking the environment in eukaryotic cells. This in turn facilitates
proper folding of eukaryotic proteins and increases their solubility. In this case, the
thioredoxin, which normally acts as a cytosolic reductant, acts as a protein oxidant [217],
consistent with its ability to act as an oxidant when exported to the periplasm [218]. Moreover,
new bacterial strains have been created which have an oxidising cytoplasm [219]. Another
possibility is in the in vitro loading of copper after protein purification. This system was used
to determine the in vitro stoichiometry of WND and MNK [157]. Fourth, it is possible that the
system used for the purification interferes with the properties of the protein. GST is an obligate
dimer and it was shown to influence the stoichiometry of copper in yCox17p [117]. Moreover,
it is possible that the protein cannot acquire the preferred ligation geometry of copper while it
is bound to the column matrix. Recently, the copper stoichiometry of ySco1p has been
determined [208]. ySco1p binds 1 copper ion per monomer. Because hSco1p can complement
the Dysco1 strain in chimeric constructs with ySco1p, it can be expected that the human gene,
too, can bind copper with this stoichiometry.
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4.3.1.1 Structure of the copper binding domain
To identify the ligands involved in copper binding, site direct mutagenesis was performed.
Thiol groups of cysteine residues are reactive Aa side chains forming complexes of varying
stability with many metal ions. In many cases cysteine residues have been described as copper
ligands. A CxxC motif has been found in the copper chaperones hHah1p, yCcc2p, Atx1p,
WND, MNK and in other metal binding proteins including zinc finger proteins, ferrodoxins
and metallothioneins. The CxxxC motif has been identified as a copper binding site so far only
in Cox2p. The involvement of the CxxxC motif of hSco proteins in the copper binding was
clearly shown in this work by the dramatic decrease of the copper content in the purified C-
terminal portion of mutants carrying alanines in place of cysteines. This was observed for both
proteins in the atomic emission spectroscopy and for hSco2p also with the atom absorption
spectroscopy. The stoichiometry for hSco2p(C)Dcys was 0,2 mole of copper per mole of
protein. The presence of residual copper hints at the presence of further copper ligands. Copper
can acquire different geometry. Atx1p can adopt a two or three coordinate copper ligand site
involving the conserved cysteines and either a methionine or an exogenous thiol, like GSH
[154]. X-ray absorption spectroscopy studies indicate that Cu(I) is two-coordinate in WND
[220]. EXAFS (X-ray absorption fine structure spectroscopy) analysis suggests the presence in
hCcsp of a binuclear cysteine-bridged dicopper cluster in which each copper is coordinated by
three cysteine ligands. The other hSco ligands are expected to bind copper weakly to allow
changes in geometry necessary for the copper transfer. ySco1p carries two further cysteines,
but they are not essential for the protein function [203]. hSco2p has a cysteine before the
copper binding motif and hSco1p has no further cysteines. A possible ligand in Sco proteins is
the histidine at position 260 in hSco1p, 224 in hSco2p and 239 in ySco1p. This histidine is
highly conserved and it was shown to be essential for the protein function in yeast and in
bacteria [104, 179]. Moreover, the environment of this histidine remembers the environment of
the two cysteines of the CxxxC motif containing a lot of acidic residues. The presence of a
negative charge around the metal binding site is perhaps important for controlling the affinity
or the geometry of the site. The trigonal coordination of Cu has been recently confirmed for
ySco1p with EXAFS analysis and the conserved histidine at position 239 was identified as the
third ligand [208]. The H239A mutant protein bound 0.14 ± 0.1 Cu per protein. In hSCO2
patients, a mutation in a serine next to the conserved histidine (S225F) is associated with lethal
COX deficiency. Atom emission analysis made in this work shows that this mutant protein is
able to bind copper. Quantification of the copper bound was not performed but the atomic
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emission data show that a dramatic reduction of copper content such as those observed in
mutants lacking cysteines is unlikely. The S225F mutation could interfere with the structure of
the coordination sphere of copper. Structural changes associated with altered geometries of the
Zn and copper binding site of Sod1p are associated with alterations in the reactivity of the wild
type enzyme, probably resulting from an altered copper binding affinity [221]. Histidines as
copper ligands have been described, for example, for Cox1p, Cox2p and hSod1p. Further
experiments, like EXAFS, are planned to identify the coordination state of the copper centre in
hSco1p and hSco2p.
In a recent model, transfer of copper involves docking of the two partner proteins with the
metal binding sites in close proximity and consequent formation of two- and three-coordinate
intermediates in which the copper ion is coordinated simultaneously from the ligand of the
chaperone and of the recipient protein [154]. This process requires the ability of the copper
centre of the chaperone to change its coordination sphere to become accessible from the ligand
of the recipient (see Fig. 38).
Fig. 38. Model of copper transfer between the chaperone and its partner protein.
The copper chaperone (yellow) binds copper (blue) for example with a trigonal geometry involving
two cysteines (C) and another ligand. The docking process between the chaperone and its partner (red)
involves electrostatic interactions between a domain of the chaperone containing for example positive
residues (+) and a domain of the partner containing for example negative residues (-). The copper
centre of the chaperone changes its conformation to become accessible for the ligands of the recipient.
Two- and three-coordinate intermediates are formed leading to a transfer of the metal centre to the
recipient protein, which can thus acquire its normal fold.
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The metal binding domain has to be at the surface of the protein, accessible for ligand
exchange reactions. An interesting question is the accessibility of the cysteines residues of the
CxxxC motif. The solvent accessibility can be deduced from the ability of the cysteines to be
oxidised and reduced. The accessible SH groups can be determined using Ellman’s reagent
[222]. Preliminary studies have shown that hSco2p is sensitive against oxygen from the air and
that the protein can be reduced by incubating in DTT-containing buffer (data not shown). This
means that the cysteine residues are readily accessible. The SH/protein ratio has yet to be
investigated. The accessibility of the metal centre is in accord with the three-dimensional
structure of Sco proteins suggested by Chinenov [176]. The proposed thioredoxin fold permits
the exposition of the two essential cysteines at a junction site between a loop and a helix (Fig.
39). A similar structure, but with another succession of the ß-sheet and a-helices, was found in
a variety of proteins that bind inorganic ions and also in copper metallochaperones.
Fig. 39. Accessibility of the cysteine residues in the metal binding site of hSco proteins.
The structural motif of the thioredoxin fold consists of a four-stranded central b-sheet and three-
flanking a-helices which are arranged in the order ß-a-ß-a-ß-ß-a. The two cysteines (in red) of the
metal binding site are solvent accessible (in part taken from [223]).
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Interestingly, copper transfer is facilitated by hydrogen bond interaction between a threonine in
hHah1p near the metal binding motif and a cysteine of the metal binding site in WND [224]. A
threonine at a distance of two Aa from the CxxxC motif is conserved in hSco proteins and
ySco1p. Site direct mutagenesis of this threonine could elucidate its function.
The E140K mutation in hSco2p changes a negative residue to a positive. Atom emission
analysis performed in this work shows that the E140K mutant protein is still able to bind
copper. Quantification of the bound copper was not carried out, but clearly the amount of
bound copper is not dramatically reduced. The influence of this mutation could be explained
by a deformation of the metal binding site. The coordination of metal in protein involves
normally the transfer of electrons of ligands to the outer orbitals of the metal. This causes an
accumulation of a partial negative charge on the metal and the presence of a positive Aa near
the copper site could contribute to an extreme stabilisation of the bond impeding the delivery
to another protein. It would be interesting to elucidate the affinity with which copper is bound
in the mutant protein. Patients carrying the E140K mutation show an accumulation of copper
as deduced from the increasing copper uptake and normal copper retention [110]. This could
mean that copper is imported in the mitochondria, transferred to hSco proteins, but it can be
more difficult to deliver it to COX. The cell responds by increasing the copper uptake and
copper concentrates in mitochondria reaching a toxic concentration. The E140K mutation, if
engineered in ySco1p, shows no effect on COX assembly [109]. However, COX activity is
slightly reduced and a small reduction was also observed in the steady-state level of the mutant
protein [109]. In human mitochondria this slight reduction might be just enough to be
deleterious in the complete absence of any other functional hSco2p. Deleterious consequences
can accumulate in time leading to a later appearance of the disease. The latter development of
the lethal COX deficiency is typical of patients carrying the homozygous E140K mutation.
The P174L mutation, which was found in hSCO1 patients and which was shown in this work
to affect the assembly of COX, is next to the CxxxC motif. This mutation was suggested to
interfere with the structure of the metal binding site [108]. Interestingly, respiratory growth of
transformants expressing K2L, but not K1L, can be rescued by adding copper to the growth
medium. The effect of copper could result from a copper-induced alteration in the overall
structure, which overcomes the interference of the P174L mutation with the three-dimensional
structure of the CxxxC-containing domain. This interpretation could also account for the
suppression of the temperature-sensitive growth phenotype of K1-transformants by addition of
copper to the YPGly medium. Alternatively - if the P174L mutation lowers the binding affinity
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of the protein for copper - an elevated copper concentration may be required to allow loading
of the protein with copper. The inability of copper to complement the K1L mutation may
reflect a suboptimal ability of K1 to substitute for ySco1p. This hypothesis is confirmed by the
lower COX activity of K1 transformants, which require copper to reach a wild-type like
growth behaviour. The K2 chimera is, therefore, the best construct to characterise hSco1p
mutations in the yeast model. The P174L mutation represents the first example of a COX
assembly mutant which can be complemented by adding copper. This finding strongly
confirms the importance of Sco proteins in the copper pathway. Interestingly, in the strain
carrying the K2L construct, the level of Cox1p and Cox2p is less reduced than in the null
mutant. The COX activity is 30 % of the wild type, suggesting that the mutated protein is able
to permit the assembly of a small quantity of COX. Therefore, the P174L mutation only
partially impairs the function of the K2L construct and its function can be completely restored
by adding copper.
Positive Aa residues could be involved in stabilising the metal centre. Clusters of lysine
residues have been described as a conserved motif in other human and yeast copper chaperones
[155]. NMR and structural analyses show that positive residues are located near the metal
binding site in Atx1p [154, 225] and are important in the activity of the metallochaperone.
Positive residues in the vicinity of the metal binding site in hHah1p have been shown to be
important for metal transfer by creating an electrostatic potential gradient that favours the
movement of the positively charged copper ion [151]. In the case of Atx1p, a lysine was
suggested to affect the kinetics or thermodynamics of copper/protein interaction through
hydrogen binding to a coordinate cysteine sulfur atom. This lysine is predicted to partially
neutralise the net negative charge that results from a coordination of two cysteinate anions to
Cu(I) and would, thereby, stabilise the copper chaperone complex. A working hypothesis is
that allosteric conformation changes at this lysine may occur during docking of the chaperone
with its partner Ccc2p [154]. A cluster of charged Aa is localised at the extreme C-terminal
portion of hSco proteins and could be implicated in this stabilisation process.
In hSod1p, mutations in a histidine ligand is associated with FALS-disease and mutant hSod1p
is devoid of copper. In this case it was suggested that the hCcsp interaction with an impaired
hSod1p target results in an inappropriate release of free copper [226]. It would be interesting to
test if all patient cells accumulate copper and if this copper is in a free or bound form.
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4.3.2 hSco proteins have no thioredoxin activity
The affinity-purified C-terminal portions of hSco proteins have also been used in an enzymatic
test to determine if the two proteins can act as thiol-disulfide oxidoreductase. The function of
Sco proteins as thioredoxin was deduced from the similarity of Sco proteins to bacterial thiol-
disulfide reductases [176]. Thioredoxins are able to reduce the disulfide bridges of insulin
faster than DTT. Reduction of insulin in presence of NADPH and thioredoxin reductase is a
widely used method to test the thiol-disulfide oxidoreductase activity. Both hSco proteins were
not able to reduce insulin, whereas a human thioredoxin, used as a positive control, was. It can
be argued that the recombinant proteins from E. coli don’t have the same properties as the
authentic human proteins. However, copper binding and enzymatic analysis of eukaryotic
proteins have often been performed using the bacterial system for the purification. Purification
of only the soluble part of the protein is also a common procedure in functional analysis [136,
227]. Insulin is a widely used substrate, because of the ability of a thioredoxin to substitute for
another with similar redox potential in vivo [228]. Another substrate used to test the
thioredoxin activity is lipoic acid, which is reduced slower by thioredoxin as compared to
insulin [229]. The insulin test was, however, shown to be ineffective in the case of two
periplasm-exposed proteins, HelXp and Ccl2p, involved in the thioreduction pathway of
cytochrome c in Rhodobacter capsulatus. In vitro studies with these purified proteins indicate
that although neither can reduce insulin, HelXp can reduce the Ccl2p cysteine residues which
in turn are oxidised by an apocytochrome c peptide containing the CxxCH domain [230].
Therefore, it can be supposed that, in the case of Sco proteins, too, the specific substrate has to
be added to detect a thiol-disulfide oxidoreductase activity. Thioredoxins have been shown to
be essential in the biogenesis of periplasm exposed proteins in bacteria. Thioredoxins-like
proteins can reduce cysteine bridges in the cytoplasm, which has reducing properties, or
oxidise proteins in the periplasm, which has oxidant properties. The ability of thioredoxins to
reduce or to oxidise depends on its redox properties and thioredoxins have been identified with
reducing properties in periplasm [134]. In eukaryotes, thioredoxins have also been found in
mitochondria where they are important in the defence against oxidative damage and stress,
acting as hydrogen donor for peroxiredoxines which catalyse the reduction of H2O2 [231, 232].
So far only one mammalian mitochondrial thioredoxin [136] and thioredoxin reductase [233]
have been identified. An interesting question is whether a thioredoxin system is required in the
biogenesis of the OXPHOS system. Formation of disulfide bonds during folding of proteins in
mammalian cells occurs in the lumen of the ER. The unique GSH/GSSG ratio (3:1) within the
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lumen of this compartment is thought to provide it with a redox potential that - in contrast to
cytosol (100:1) - is oxidising enough to favour disulfide bonds [234]. Moreover, the ER lumen
contains a variety of chaperones that assist and accelerate the folding reactions [235].
Cytoplasm is generally considered to be too reducing to allow the formation of disulfide
bonds. However, proteins from vaccinia virus (vv) are able to form disulfide bonds in the
cytoplasm of infected cells [236]. Since the redox state of cytoplasm of vv infected cells
remain normal, these proteins probably possess an inherent property to acquire disulfide bonds.
In vitro studies have shown that the formation of intramolecular disulfide bonds depends on
the conformation as well as on the inherent disulfide oxidation-reduction potential of the
protein [237]. The disulfide bond formation of the vv proteins under cytosolic (reducing)
condition can be rationalised by assuming that the redox potential of the these proteins
themselves must be higher than the cytosolic redox potential and that the conformation of the
proteins favours the intramolecular bonding and folding. These data show that the equilibrium
between disulfide bonds and sulfhydryl is a complicated pathway which can be independent on
the redox state of the compartment and which can occur spontaneously or catalysed by
chaperones. In yeast the only genes found to be necessary for cytochrome c biogenesis are the
heme lyases. So far disulfide reductase activity of the heme lyase was not shown and it is thus
possible that the cysteines of apocytochrome c and COX are already in a reduced state without
requiring assisting proteins.
4.4 Interaction analysis of hSco proteins
4.4.1 Interaction between hSco1p, hSco2p and Cox2p.
The results of the functional analysis strongly hint at the conclusion that the two hSco proteins
act as copper chaperones. Sco proteins could transfer copper to Cox1p and/or Cox2p. To test if
hSco proteins are involved in the transfer of copper to Cox2p, interaction was studied using
affinity chromatography and coimmnunoprecipitation. With the affinity chromatography
analysis no interaction was detected. It is possible that the in vitro test is not the best system to
study this interaction because only the C-terminal portion of hSco proteins fused to GST was
used in the test. The TM could be important for the protein-protein interaction and the N-
terminal portion may be necessary for the correct protein folding. Interestingly, the N-terminal
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portions of hSco1p and hSco2p are very different and bacterial Sco homologues like SenC and
YpmQ lack the N-terminal portion. It could be useful to repeat the test fusing the soluble part
of Cox2p to GST and incubating it with lysate of HeLa cells expressing a tagged version of the
full version of hSco proteins. Moreover, as GST is an obligate dimer, it can alter the properties
of the fused proteins. Therefore, it may be advantageous to use another tag like chitin binding
protein or maltose binding protein.
The results of the coimmunoprecipitation show a very weak interaction only between hSco1p
and Cox2p. Perhaps the interaction between hSco2p and Cox2p was too weak to be detected.
The interaction could be transient and, therefore, hard to detect. This possibility was suggested
for the interaction between hHah1p and WND and MNK, respectively. The transient nature of
the interaction would permit diffusion-driven movement of cellular copper via association and
dissociation of hHah1p with the ATPases. Such an interaction is consistent with
immunofluorescence data which reveal no detectable hHah1p concentrated at the trans-Golgi
network and by coimmunoprecipitation studies which indicated that only 3-5 % of hHah1p
coprecipitate with the ATPases [152]. Moreover, a transient interaction between ySco1p and
Cox2p was postulated [208]. Detergent-solubilized mitochondrial lysates were subjected to
size exclusion chromatography and column fractions analysed by SDS-PAGE and Western
blotting. ySco1p eluted in fractions corresponding to a molecular mass larger than 200 kDa.
The fractions containing ySco1p also contained Cox2p. However, if mitochondrial lysates
from strains lacking Cox2p were analysed under the same conditions, the size of the ySco1p
containing complex was unaffected, suggesting that these two proteins were not in the same
complex [208]. However, interaction between ySco1p and Cox2p was detected in the
immunoprecipitation test [104].
In this work about 1 mg of mitochondria was used for the in vivo test. In the case of the
immnunoprecipitation of hSco1p-EGFP, the cell line HeLa 17A3 was used, which express
hSco1p-EGFP stably. For the immunoprecipitation of hSco2p-EGFP, transfected HeLa cells
were used. Because the transformation efficiency is about 50 %, only half of the used
mitochondria will contain hSco2p-EGFP. Perhaps it can be useful in further experiments to use
more mitochondria to detect the interaction. One other problem can be the tag used for the
immunodetection of hSco proteins. EGFP is a 27 kDa protein, and it could destroy the
structure of the hSco proteins or interfere with the conformation necessary for the protein-
protein interaction. Smaller tags like AU5 or HA could be used in the place of EGFP. The HA
epitope seems not to be suitable because preliminary studies showed that the antibody against
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HA recognise a lot of unspecific bands in HeLa cell lysate. Moreover, it can be expected that
only copper-lacking Cox2p can interact with hSco proteins. If all proteins contain bound Cu(I),
the interaction may be destabilised. Therefore, it might be useful to remove copper from COX.
A copper chelator widely used to test copper dependent interaction is BCS. BCS was used to
reveal the interaction between hHah1p and MNK. In this case the interaction was copper-
dependent and immunoprecipitation was performed from lysate from cells grown in the
presence of BCS or in the presence of high copper concentration [152]. However, it cannot be
excluded that starvation of copper with BCS leads to an instable COX complex. Another
possibility may be to grow the cells in a medium with a small quantity of copper and add
copper immediately prior to the immunoprecipitation to have a higher amount of assembling
COX complexes.
4.4.2 Interaction between hSco1p, hSco2p and hCox17p.
ySCO1 and ySCO2 can rescue a ycox17 null mutant [84]. Since a Dysco1 strain is not rescued
by yCOX17, ySco1p is likely to act downstream of yCox17p [84]. Cox17p could target copper
specifically to mitochondria and transfer the metal to Sco proteins. yCox17p binds three
copper ions forming a polycopper cluster [115]. This cluster exhibits many features of the
copper thiolate cluster of the Cup1 metallothionein [238]. Each molecule forms a cluster with
trigonal Cu coordination by cysteinyl thiolates and the clusters are pH-stable. The difference
consists in the lability to ligand exchange reactions using BCS. Two of the three Cu ions are
very reactive to exogenous ligands, showing that yCox17p is implicated in copper transfer
rather than acting as a metal-scavenging protein in the mitochondria. Interaction between
hSco1p, hSco2p and hCox17p was detected only in the absence of DTT in the affinity
chromatography assay. The importance of DTT in the interaction probably did not result from
a negative influence of DTT on the structure of the proteins. DTT should not demetallate the
proteins, because it is a weak Cu(I) chelator. Moreover, the stoichiometry of yCox17p was
demonstrated using proteins purified in the presence of DTT [115] and in this work the
stoichiometry of hSco1p and hSco2p was performed in PBS-DTT. yCox17p was shown to
form oligomer complexes [115]. The oligomerisation state was independent of the presence of
DTT. The importance of DTT rather consists in its reducing properties. If the interaction
between Sco proteins and Cox17p occurs via disulphide bridges, DTT could disrupt this
interaction. This idea is supported by the observation that the interaction between hSco
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proteins and hCox17p is stronger in the presence of copper. Copper, like other transition
metals, can catalyse the formation of unspecific disulfide bridges in aerobic conditions.
Interaction between yCox17p and ySco proteins was demonstrated in the yeast system in vitro
[203]. Again, it can be postulated that the presence of a very large tag like EGFP (27 kDa
versus 8 kDa of hCox17p) destroys the native structure of hCox17p. EGFP dimerises at high
concentration and because of the very high expression of hCox17p-EGFP in Hela cells, it can
be expected that the EGFP part of the fusion protein form dimers and can induce a non-native
conformation of hCox17p, thereby altering the properties of the polycopper cluster. Moreover,
the oligomeric state of Cox17p in mitochondria could be an important feature for the
interaction with Sco proteins and the formation of oligomers could be impaired by the presence
of EGFP.
An interesting question is why overexpression of ySco proteins is able to complement a ycox17
deletion mutant. Sco proteins, if overexpressed, could bind copper directly in the cytoplasm
and overcome the absence of Cox17p. Moreover, the published null allele of yCOX17 is a
disruptant with three-fourth of the protein including 6 of the 7 cysteines still disposable [86].
Perhaps the remaining protein could bind copper with a reduced affinity and more copper (the
strain can be complemented too with a copper rich medium) or more partner protein could be
required to reach a good efficiency of the copper delivery. The question remains open if other
copper transporters for the mitochondria exist. Cu chaperones appear to be particularly
important at low concentration of extracellular copper. Under elevated copper concentration
their contribution to Cu transport is reduced, possibly because of the increasing role of non
specific Cu-binding carriers. The Cu/Zn-superoxide dismutase activity, for example, was
restored by addition of Cu (but not by addition of other metal cations) to the growth medium of
yeast strains lacking the ySod1p chaperone Lys7p [239]. GSH is a highly abundant thiol agent
in mammalian cells and can form very stable complexes with Cu(I). GSH was found to be a
more efficient copper donor to the copper-free enzyme Cu/Zn-superoxide dismutase than other
low molecular weight Cu(I) complexes in vitro [240]. Evidence was obtained for the
occurrence of a Cu(I)-GSH protein intermediate in the reconstitution process. On the contrary,
copper-thionein was unable to reconstitute Cu/Zn-superoxide dismutase. Copper-GSH
complexes were detected in hepatoma cells over-loaded with copper [241]. A majority of the
cytoplasmic copper (more than 60 %) was isolated as a GSH complex. Kinetic studies of 67Cu
uptake showed that GSH bound 67Cu before the metal was complexed by MT. These results
support a model of copper metabolism in which the metal is complexed by GSH soon after
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entering the cell. The complexed metal is then transferred to higher molecular weight
components such as metallothioneins, where it is stored, and as Cu/Zn-superoxide dismutase
[242]. Because the outer mitochondrial membrane is porous to small molecules, it is possible
that Cu(I)-GSH can act as a copper transporter for this compartment. Moreover, recent studies
suggest that the transfer of metals from MT to an acceptor is possible and GSH facilitates such
transfer reaction [243, 244]. These data suggest that MT could prevent metal toxicity and/or
donate the metal to metalloproteins. MT have been shown to localise inside mitochondria
when copper is in excess [245]. How Cox17p enters mitochondria is not clear because the
outer membrane is porous only for small molecules up to a size of 12 kDa [246] whereas
yCox17p is shown to be a dimer in the cytoplasm with a MW of 16 kDa [115]. Moreover,
transport of copper in other compartments, like the secretory pathway, is a very controlled
mechanism and it can be expected that in mitochondria, too, a specific copper pump is
required. Indeed it was demonstrated that a form of the WND is localised in the mitochondria
[48]. WND is localised normally in the Golgi and has a MW of 160 kDa. A version of 140 kDa
was detected in mitochondria of cultured hepatic cells and human tissues. The 140 kDa WND
product is formed as a result of proteolytic cleavage at the N-terminal portion of the full length
WND. The cleavage of the WND protein presumably removes one or two of the six metal-
binding repeats from the N-terminal domain [48]. WND and the other copper pump MNK
have been shown to move from their localisation in the Golgi in the presence of high
concentration of copper [148, 149]. If a parallel copper pathway exist in mitochondria, Sco
proteins would be able to receive copper from proteins other than Cox17p. Possibly the
alternative way is switched on in the absence of Cox17p. It will be interesting to look for other
copper containing proteins in mitochondria. Homologues of Cox17p were not found in bacteria
[179] and deletion of the bacterial Sco homologue YpmQ from Bacillus subtilis can be
overcome by supplementing the growth medium with copper [179]. This finding can reflect the
simpler structure of prokaryotic cells.
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4.4.3 Homomerisation and heterodimerisation of hSco proteins.
Affinity chromatography analysis performed in this work shows that the carboxyl-terminal
portion of hSco proteins can form homomeric complexes. Because HeLa cell lysates were used
in the experiments as the source of the tagged hSco proteins, it is not excluded that complex
formation is mediated by other proteins present in the lysate. The interaction - whether direct
or indirect - does not require the CxxxC motif, as shown by the formation of homomeric
complexes by the hScoDcys mutant proteins. A further analysis with gel filtration
chromatography of the affinity purified hSco proteins leads to the conclusion that hSco1p
forms dimers directly because the protein eluted from the column as a 1:1 mixture of monomer
and dimer and no other component could be detected. In contrast hSco2p eluted mostly as a
monomer, with a small amount of dimer. This result can hint at the conclusion that other
factors can be involved in the dimerisation of hSco2p or that the C-terminal portion alone is
not sufficient to promote the dimerisation. In the in vitro assay hSco2p is present as a full-
length construct fused to EGFP and as a GST fusion of the C-terminal portion. Therefore, the
presence of one N-terminal portion could be sufficient to promote the formation of the dimer.
The dimeric state of hSco proteins is in agreement with the recent finding that ySco1p form
oligomers complexes. In this case, too, it was proposed that the formation of the oligomers
requires the presence of the N-terminal portion [208]. Dimerisation of copper binding proteins
is not without precedent: recently it was reported that the copper enzyme superoxide dismutase
as well as its chaperone Ccsp form homo- and heterodimers [165]. Dimerisation of yCcsp was
copper dependent in vitro [161]. The homodimerisation of hSco2p could explain the
correlation between genotype and phenotype in the patients. As outlined in the introduction, all
patients have a common mutation and a further stop mutation or point mutation. People
carrying only one mutation do not present a phenotype, showing that a single wild type copy is
sufficient. Patients with two E140K mutations have a milder phenotype, in that they develop
the disease at a later time point. Possibly hSco2p with the E140K mutation still can
homomerise. Patients with a further point mutation live only for three months, and patients
with a further stop mutation only for few days. In these cases the presence of the E140K
mutant allele is no longer sufficient to allow assembly of COX. Probably the E140K mutant
protein can dimerise with itself, but significant percentage will homomerise with the other
mutated protein leading to an inactive dimer. This suggests that the functionality of the
hSco2p(E140K) mutant form is disturbed by the presence of a further mutant protein and that
dimerisation is important for the protein activity.
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In this work, the hSco2p(E140K) and hSco2p(S225F) mutant forms were shown to be stable as
EFGP fusions, however their stability can derive from the presence of the EGFP tag. It was
observed that the concentration of the hSco2p(E140K) mutant form in the GST construct was
somewhat reduced, suggesting an effect of the E140K mutation on the stability of the protein.
It was demonstrated that the E140K and S225F mutations do not lead to a mislocalisation of
the two proteins. Mutants carrying the E140K mutation and the S225F mutation can dimerise
with the wild type protein and with each other. This supports the idea that the mutations do not
influence the dimerisation, but rather the formation of an active dimer. Moreover these
mutations could interfere with the heterodimerisation process. The importance of dimerisation
in copper delivery has been discussed for yCcsp (Lys7p) and yCox17p. In the case of Lys7p,
dimerisation of the protein is induced by the presence of copper [161]. On the basis of (a)
observations that full-length Lys7p can be dimeric in both crystalline and solute environments
[162], (b) features in the Lys7p structure that suggest a putative docking site for an ySod1p
dimer with a Lys7p dimer [247], and (c) the spatial arrangement of the putative copper
delivery domain(s) in the dimeric Lys7p structure [162], a model for Lys7p-ySod1p interaction
and copper delivery was suggested. It implicates a dimer-dimer interaction that obviates the
need to disrupt the very stable ySod1p homodimer and that allows simultaneous copper ion
delivery to both ySod1p subunits [247]. Bovine COX exists as a dimer [248] with the two
copper centres separated by 74 Å. The dimer interface is formed by Cox4p which also forms a
tight interaction with Cox2p [248]. Heaton et al. (2001) [115] suggested that the CuA site
formation, if the Cu insertion into CuA takes place in the assembled COX complex, may
involve the dimeric COX complex. Thus the oligomeric state of Cox17p may be important in
the Cu(I) delivery to two Sco molecules docked on Cox2p at the dimer interface.
The copper chaperone Ccsp directly interacts with copper/zinc superoxide dismutase [165].
Interestingly, Ccsp has a high degree of similarity to Sod1p, reminiscent of the situation with
hSco1p and hSco2p. In effect, hSco1p and hSco2p were shown to form heterodimers in vivo
and in vitro. Again no data are available to determine if the interaction is direct or mediated
from other factors present in the lysate of HeLa cells.
Docking of proteins involves generally electrostatic interaction. This interaction was described
for hHah1p and WND [151] as well as for Atx1p and Ccc2p [249]. In this case the docking
process was supposed to involve electrostatic interactions between the basic face of the
metallochaperone and the corresponding acid face in its target protein [225]. The R175W
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mutation in hSco2p is localised in a cluster of charged amino acids and could interfere with the
protein-protein interactions. This mutation was not examined in this work, analysis of its
copper binding and homodimerisation properties are planned. Interestingly, other clusters of
charged Aa are localised near the TM and at the extreme C-terminal portion of Sco proteins.
Both were shown to be essential for ySco1p function [203]. The interaction between Cox2p
and hSco proteins, both membrane proteins, could involve the TM and the positive charge of
hSco proteins next to the TM could mediate the protein recognition. Another chaperone/target
recognition mechanism implies a structural similarity between the two partner proteins, as
described for Ccsp and Sod1p. Sco proteins exhibit sequence homology with a 20 Aa portion
of the CuA domain of COX centred around the pair of cysteine residues of the copper binding
site but the structural similarity is too limited to support this mechanism.
A schematic overview of domains possibly involved in the action of Sco proteins is given in
Fig. 40.
Fig. 40. Schematic presentation of important domains of hSco proteins.
hSco proteins (yellow) are probably localised in the inner mt membrane (IM, grey). The C-terminal
portion could protrude in the intermembrane space (IMS) and the N-terminal portion is in the matrix,
as described for ySco1p. Copper (blue) is possibly bound by two cysteine residues (C) and one
histidine (H). Positively (+) and negatively (-) charged domains are indicated. Mutation identified in
human COX deficiency are shown with a red X. The possible role of the different domains is
indicated.
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4.5 Role of hSco1p and hSco2p
The results of the functional analysis strongly suggest that the two hSco proteins bind copper.
No thioredoxin activity was detected and it can be proposed that hSco proteins act as copper
chaperones.
Sco proteins could transfer copper to Cox1p and or Cox2p. In this work only the interaction
between hSco proteins and Cox2p was analysed. A weak interaction in vivo was found
between hSco1p and Cox2p. In yeast, an interaction between ySco2p and Cox2p was also
found [203], but it cannot be excluded that the high homology between ySco1p and ySco2p led
to an unspecific interaction or that the yeast and the human systems are not identical.
Several indications suggest that Sco proteins deliver copper to Cox2p. First, the deletion of the
Bacillus subtilis Sco1 homologous YpmQ suppresses the activity of the cytochrome c oxidase
but not of a second oxidase, the menaquinol oxidase, which only contains a CuB centre [179].
Second, the S225F mutation, when engineered in ySco1p, led to a partial COX assembly, with
reduction of only Cox2p [92]. The insertion of CuB requires the Cox11p protein. In
Rhodobacter sphaeroides, the deletion of the respective gene led to a cytochrome c oxidase
containing CuA but lacking CuB [87]. Deletion of yCOX11 eliminates the accumulation of
detectable COX in the mitochondrial membrane [250]. Cox11p has a conserved CxC motif
which resembles the metal binding region of other metal chaperones and can act in the binding
of copper. It cannot be excluded that Cox11p receives copper from Sco proteins. However, a
role for Cox11p in the formation of CuB does not require it to bind copper. It was also
proposed that by interacting with Cox1p, Cox11p permits a conformation receptive for copper
delivery by a different protein [87]. It would be interesting to test copper binding of Cox11p
and the eventual interaction between Cox17p and Sco proteins and Cox11p. The different
pathways of copper insertion for CuA and CuB can reflect the different structural features of the
two copper centres. For example, CuA is located in an aqueous environment exposed domain
about 5 Å from the surface of the protein, whereas CuB is bound within a transmembrane helix
of Cox1p at a distance of about 15 Å from the closest water-exposed surface of the protein
[248, 251]. Assembly of CuB occurs either in the matrix where Cox1p is synthesised, or in the
membrane. The analysis of the orientation of Cox11p and Sco proteins could help to reveal
whether the incorporation of copper takes place, before, in the matrix side, or after the
assembly of Cox1p and Cox2p. The extra membrane domain of ySco1p faces the
intermembrane space. This conclusion is supported by the sensitivity of ySco1p to proteinase
K in mitoplasts but not in intact mitochondria [113]. This suggests that the proposed copper
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binding site of ySco1p and the copper site of Cox2p face the same mitochondrial compartment.
Such a localisation would be in accord with the proposed model in which Cox17p targets
copper specifically to mitochondria by transferring the metal to Sco1p. In this work, an
interaction with hCox17p was not found. However, as discussed above, the condition of the in
vitro assay are possibly not optimal to test this interaction. Cox17p remains, therefore, a good
candidate for the transfer of copper to Sco proteins, even though it cannot be excluded that
other copper transporters, like WND, exist in human mitochondria. Sco proteins could also be
carriers that transport copper to the matrix. This theory would be in agreement with the
recently described oligomerisation state of ySco1p [208] which would allow to the Sco
proteins to form a pore in the inner membrane. If copper addition occurs after membrane
insertion of Cox2p, a role of Sco1p as a copper transferase would be more attractive than the
pore model. The S225F mutant, engineered in ySco1p (S240F), is the first reported yeast COX
assembly mutant that can partially complete the assembly pathway without complete
proteolytic loss of the catalytic core of the molecule [92]. The S240F mutant selectively lacks
Cox2p and it was proposed that the absence of the CuA centre led to unoccupied sites that are
susceptible to proteases. Unlike GR20, the strain bearing the S240F allele has a stable mutated
ySco1 protein, suggesting a stabilising influence of ySco1p on the assembling holoenzyme.
These results suggest that ySco1p acts perhaps at the last step in the assembly pathway since
all of the other subunits of the holoenzyme are present and assembled. However, it cannot be
excluded that copper is inserted but with a wrong coordination, allowing the assembly of the
others subunits but not protecting Cox2p from degradation.
The presence of two homologues raises the question whether they have the same function. The
diversity of the phenotypes resulting from hSCO1 and hSCO2 mutations suggest that the
proteins do not have the same role. So far mutations in two other assembly factors have been
correlated with COX deficiency and in each case the phenotype is different even though in all
cases the COX activity is reduced, pointing to a different mechanism of COX impairment.
Moreover, these mutations have different effects on the COX assembly: while the
concentration of all COX-subunits except for Cox5ap and Cox5bp is strongly reduced in
hSURF1 patients [98], mutations in the hCOX10 gene preferentially affect the level of Cox2p
[80]. In patients with hSCO2 mutations, immunohistochemistry revealed a severe reduction of
Cox1p and Cox2p, while Cox4p and Cox5ap were less affected [95]. The pathogenic hSCO1
mutation, if introduced in a ySco1p/hSco1p chimera, affect the level of Cox1p and Cox2p (this
work). Different assembly profiles are typical of COX deficiencies and reflect the genes which
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are potentially involved. Some patients have normal levels of all COX subunits and are
classified as candidates for mutations in nuclear encoded structural genes. Other patients have
reduced levels of several subunits and are classified as assembly mutants [252]. The decreased
steady-state level of the subunits observed in patients is likely the result of proteolytic
degradation of unassembled or misfolded subunits. Studies in yeast have revealed the existence
of an ATP-dependent proteolytic pathway responsible for the clearing of unassembled and
improperly folded polypeptides in the various subcompartments of mitochondria [175]. This
proteolytic system is responsible for the rapid degradation of COX subunits in yeast strains
unable to complete assembly of the holo-enzyme due to a lack of one of the subunits or of
assembly-assisting proteins [253]. In yeast COX assembly mutants are characterised by a
selective degradation of the mitochondrially encoded subunits 1 and 2, while the nuclearly
encoded subunits are normally present at or near wild type levels. The proteolytic system
appears to be conserved in mammals [45]. Low levels of nuclear-encoded COX subunits have
been found in human cell lines that do not express the mtDNA encoded subunits [254] and it
was demonstrated that these low steady-state levels are the result of an increased turnover rate
[255]. Furthermore, it was shown that the reduced COX content in fibroblasts cultures from
patients with COX deficiency suffering from Leigh syndrome was the result of an elevated rate
of degradation [172]. In most patients the steady-state levels of subunits 4, 5a and 5b were less
affected. Subunit 4 appears to have an intrinsic stability and is present at 40 % of control
values in human cell cultures depleted of mtDNA [256]. Subunits 5a and 5b do not span the
inner membrane and are located on the matrix site of the enzyme complex [62]. These subunits
may already be folded prior to assembly making them less prone to proteolytic degradation.
hSURF1, hCOX10 and hSCO1 mutations lead to an overall decrement of the COX activity,
only hSCO2 patients show a tissue specific reduction with strong involvement of myoblasts
and skeletal muscle. hSURF1 mutations cause lesions in cerebral basal ganglia, known as
Leigh syndrome. Age at onset is usually between 8 and 14 months. hSCO2 mutations are
associated with hypertrophic cardiomyopathy. Age at onset is generally between birth and the
first months of life with death occurring between 1 and 6 months. Interestingly, hSCO2
patients carrying the E140K mutation show a normal development in the first months, later
they develop a Leigh syndrome and the fatal cardiomyopathy occurs in the final stadium. In
these patients a predominant involvement of the peripheral nervous system was observed and it
was hypothesised that the progressive cardiomyopathy in hSCO2 patients is not necessarily an
early symptom of this disorder, but it may be indicative of a specific aerobic energy supply
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threshold for cardiac function [110]. Threshold effect of mitochondrial mutations is a well
investigate process [257]. Mitochondrial cytopathies present usually a tissue specificity. Even
if a mutation is present in all tissues, only some will be affected and show a pathology. The
tissue specificity can be explained with the expression of the defect in OXPHOS complexes
that present individual biochemical thresholds. The value of this threshold for a given
OXPHOS complex can vary according to the tissue; thus different tissues will display different
sensitivities to a defect in an OXPHOS complex. A classification of tissues according to their
response to a OXPHOS complex deficiency and, therefore, to their threshold values has been
proposed [258]. For a given OXPHOS complex, the lower the threshold value in a tissue, the
more sensitive this tissue is to a defect of this complex. For complex IV threshold values in the
muscle and in the heart are lower than in the kidney and brain. For example, it was shown that
an 80 % decrease in COX activity will induce a small decrease in mitochondrial respiration in
liver, while the respiration drops to 40 % in heart mitochondria [258].
Little information is available for hSCO1 mutations because so far they were found only in two
boys from the same family. However, the course of the disease was very fast, with death after
4 days from the birth in one case. The combined data from patients lead to the conclusion that
both hSCO genes are essential for COX assembly. The different involvement of tissues
addresses the question if both proteins are expressed in all tissues. Northern blot analysis
shows that both genes are expressed in the same tissues [95], but a post-translational regulation
could be postulated. There is no direct relation between steady-state transcript and protein
levels. Mechanism ensuring post-transcriptional or post-translational regulation must,
therefore, be envisioned to account for the discrepancy between these two parameters. In
human, three nuclear coded subunits of COX (6a, 7a and 8) occur as tissue-specific isoforms.
COX presents different kinetic parameters according to its L (liver) and H (heart) isoform
composition [259]. Subunit 6a has potential regulatory function [72, 260] controlling COX
activity in response to ATP binding. Mutations in such tissue- and developmental-specific
subunits have been proposed to account for some COX deficiencies [261, 262]. Mutations in
nuclear genes have so far not been reported, but they are strongly suspected to account for
COX deficiencies [252]. Specific isoforms could optimise the enzymatic activity to the
metabolic demands of different tissues. In analogy, hSco1p and hSco2p could represent
isoforms of high and low energy requiring tissues.
Even though fibroblasts are less affected than myoblasts in hSCO2 patients, they still show a
reduction of 50 % of the reference value, indicating an influence of hSco2p. It could be
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supposed that hSco1p represents the general way for copper delivery and that hSco2p is a
redundant protein in those tissues which do not require high energy, but it is indispensable in
tissues with a high energy demand. This would explain why in yeast the deletion of ySCO2
does not have any effect on the respiration and why hSCO1 mutations lead to an overall COX
deficiency, whereas hSCO2 mutations lead to a tissue specific COX activity reduction.
Because both proteins were shown to homomerise, it is possible that the transfer of copper
requires the formation of dimers. The presence of an assembled COX complex, lacking only
Cox2p [92], suggests that CuA is inserted in a last step of the assembling process, when COX
is already a dimer. Dimer or higher complexes of Sco would be required to interact with the
COX dimers. Alternatively, hSco dimers can be required to transfer at the same time two
copper atoms to the two-copper centre of Cox2p. Since oligomerization of Cox17p is
important for its function [115], the possibility exists that Cu(I) ions are donated from the
Cox17p tetramer to the Sco1p oligomer.
The detection of heterodimers complexes in vivo and in vitro underlines the importance of the
interaction between the two homologues. hSco1p dimers could receive copper inefficiently
from a mitochondrial copper chaperone like hCox17p or more efficiently from hSco2p dimers,
which may represent a high affinity binding site for hCox17p. In fibroblast, the less efficient
copper transfer from the chaperone to hSco1p is sufficient for the COX activity. The transfer
of copper from hSco2p to hSco1p becomes indispensable in high energy requiring tissues or
under conditions of limiting copper. Research in yeast has shown that the respiration
competence of a Dysco2 strain is reduced in a medium poor of copper (Lode, personal
communication). In the case of hCcsp, it was shown that a domain of the protein acts as
sequestering site only under the condition of copper limitation [161], and another domain as
translocation site. The sequestering site transfers the copper to the translocation site via a three
coordinate intermediate. A comparable situation could be represented in mitochondria by
hSco1p/hSco2p heterodimers. It can be expected that this specific copper pathway can be
bypassed in high copper condition by the presence of unspecific copper carriers like GSH.
Assembly of COX may differ in high and low energy requiring tissues. The finding that
hSURF1 mutations cause an overall COX deficiency shows that at least some of the assembly
steps are identical in the various tissues. hSurf1p is possibly implicated in the insertion of
Cox1p and Cox2p in the holoenzyme, a process that can be the same in all tissues. The
formation of the copper centres, instead, can require a more efficient pathway in tissues like
brain and heart. In these tissues more COX complexes have been expected to be produced and
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the copper disposability can be a limiting parameter. This hypothesis is supported by the tissue
distribution profile of hCOX17 mRNA. Hybridisation signals were detected in all tissue RNA
samples, but they were drastically more intense in heart, kidney and brain [263]. The tissue
distribution profile of hCOX17 mRNA is quite different from that of hHAH1 [145] and hCCS
[160]. The mRNA of these cytosolic chaperones has the same abundance in all tissues. The
mRNA distribution profile of hSCO1 and hSCO2 overlaps with that of hCOX17. This suggests
that in high requiring energy tissues the copper transport pathway is more active.
The presence of a parallel copper transfer pathway for high energy demand tissues cannot be
excluded. Different routes of copper transport could be used in different tissues. This
possibility was, for example, proposed in the case of MNK, because the mRNA transcripts
were found in all tissues except in liver [264]. In analogy, hSco2p could receive copper
specifically from a so far unidentified copper transporter which is expressed in high energy
requiring tissues and transfer it to hSco1p.
A model for the function of the hSco proteins under several conditions is represented in Fig.
41.
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Fig. 41. Possible mechanisms of copper transfer from Sco proteins to COX.
A. Copper (in blue) is imported in the mitochondria by hCox17p which forms oligomers and transfers
copper to the high affinity hSco2p-dimer and, partially, to the low affinity hSco1p-dimer. hSco2p-
dimers transfer copper selectively to hSco1p-dimers. The specific transfer of copper from hSco2p
dimers to hSco1p-dimers is indispensable in condition of low copper and/or in high-requiring energy
tissues. hSco1p-dimers interact with COX through the TM portion and transfer two copper ions to the
dicopper centre of Cox2p. B. In the presence of high amount of copper, hSco1p can receive copper
from non-specific Cu-binding carriers, like GSH.
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The finding that copper addition to the medium can complement the P174L mutation can
provide a strategy for the early treatment of infants carrying hSCO1 and hSCO2 mutations.
Treatment with copper-histidinate is recommended in Menkes disease and was tested with two
hSCO2 patients [110]. No beneficial effects were observed, but the copper supplementation
began at a late stage of the disease, when the damages were probably irreversible. Very
recently, it was shown that addition of copper-histidinate to the medium of cultured myoblasts
of patients, harbouring the E140K mutation and a stop mutation at Aa position 90, completely
restored COX activity [265]. This result supports the model proposed in this work, according
to which hSco1p can substitute for hSco2p in the presence of high copper concentration.
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5 SUMMARY
COX deficiency in human presents a plethora of phenotypes which is not surprising given the
complexity of the enzyme structure and the multiple factors and many steps required for its
assembly. A functional COX requires three mitochondrially encoded subunits (Cox1p, Cox2p
and Cox3p), at least 10 nuclearly encoded subunits, some of which are tissue specific, and a
yet unknown number of assembly factors. Mutations in four of these factors, hSco1p, hSco2p,
hCox10p and hSurf1p, have been associated with lethal COX deficiency in patients.
Sco proteins, conserved from prokaryotes to eukaryotes, are probably involved in the insertion
of copper in COX. The role of hSco1p and hSco2p in this process was investigated in this
work. Moreover the importance of some hSco mutations found in patients was analysed.
Both in vitro and in vivo analyses show that the hSco proteins are localised in the
mitochondria.
Both proteins are per se unable to substitute for ySco1p. However, a chimeric construct
consisting of the N-terminal portion, the TM and a part of the C-terminal portion of ySco1p
and the remaining C-terminal part derived from hSco1p was able to complement a Dysco1
strain. This construct was used to define the role of a point mutation (P174L) found in the
hSCO1 gene of infants suffering from ketoacidotic coma. These mutation was shown to affect
the COX activity and the levels of Cox1p and Cox2p. The fact that copper was able to suppress
this mutation, strongly outlined the importance of Sco proteins in the copper insertion in COX.
The C-terminal portions of recombinant hSco1p and hSco2p were purified from E. coli by
affinity chromatography. The purified proteins were subjected to atomic emission and
absorption analyses and were shown to specifically bind copper. A stoichiometry of 1:1 for
hSco2p and of 0,6:1 for hSco1p was determined.
To identify the Aa residues involved in copper binding, in vitro mutagenesis was performed.
hSco1p and hSco2p, lacking the cysteines of the predicted metal binding site CxxxC, show a
dramatic decrease in the ability to bind copper. A model for the structure of the metal binding
site in hSco proteins is proposed. hSco proteins could bind copper with trigonal coordination,
involving the two cysteines of the CxxxC motif and a conserved histidine.
The purified recombinant proteins were also used in an enzymatic assay to test their ability to
reduce disulfide bridges, similar to thioredoxin-like proteins involved in the assembly of
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bacterial COX. Both hSco proteins were not able to act as thioredoxins suggesting a role for
the hSco proteins as copper chaperones.
To define the pathway of the copper transfer to COX, hSco proteins were tested for their
ability to interact with hCox17p, a mitochondrial copper chaperone, and with Cox2p, which
contains two copper ions. An interaction between hSco1p and Cox2p was detected.
Both hSco proteins were shown to homomerise and to form heterodimers one with each other.
Two mutations found in hSCO2 patients suffering from hypertrophic cardiomyopathy, (E140K
and S225F) were shown not to affect the copper binding properties, the intracellular
localisation and the ability to form homomers.
In accordance to these data, a model is proposed in which hSco2p dimers transfer copper to
hSco1p dimers. hSco1p dimers interact with COX and insert copper in the binuclear centre of
Cox2p.
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